Personale

Recapiti

Italiano

Curriculum

Pubblicazioni

Insegnamenti

English

Curriculum

Francesco MANNELLI

Ruolo attuale:: Ricercatore Legge 240/10 a tempo determinato
SSD:: MEDS-09/B - Malattie del sangue
Afferenza organizzativa:: Dipartimento di Medicina Sperimentale e Clinica

Recapiti

francesco.mannelli(AT)unifi.it

Francesco MANNELLI

Curriculum

Il sottoscritto Mannelli Francesco

codice fiscale MNNFNC76T17G999I

nato a Prato il 17/12/1976, residente in Strada dei Decoratori n 28, Località Sesto Fiorentino Prov. FI CAP 50019

consapevole delle responsabilità penali cui può andare incontro in caso di dichiarazioni non veritiere, ai sensi e per gli effetti di cui all’art. 76 del D.P.R. 445/00 e sotto la propria personale responsabilità

DICHIARA

i seguenti stati, fatti e qualità personali:

Titoli di studio:

Laurea in Medicina e Chirurgia conseguita presso Università degli Studi di Firenze

voto 110/110 cum laude in data 23/04/2002

Specializzazione in Ematologia conseguita presso Università degli Studi di Firenze

voto 70/70 cum laude in data 31/10/2006

Iscrizione all’Albo dell’Ordine dei Medici n 12908 di Firenze dal 14/12/2009 (precedentemente iscritto al n. 981 dell’Albo dei Medici Chirurghi di Prato dal giorno 1/4/2003)

Esperienze lavorative e/o professionali:

Dal 01/11/2023 a oggi – Università degli Studi di Firenze Largo Brambilla 3, 50134, Firenze: Ricercatore a tempo determinato di tipologia B per il settore scientifico disciplinare MED/15 presso il Dipartimento di Medicina Sperimentale e Clinica.

Dal 12/12/2016 al 31/10/2022 - Azienda Ospedaliero-Universitaria Careggi (SSN), Largo Brambilla 3, 50134, Firenze: Dirigente medico presso la SOD Ematologia, Centro di Ricerca e Innovazione nelle Malattie Mieloproliferative (CRIMM).

Dal 28/01/2016 al 11/12/2016 - Azienda Ospedaliero-Universitaria Careggi (SSN), Largo Brambilla 3, 50134, Firenze: Contratto libero professionale di medico ematologo a tempo pieno presso la SOD Ematologia per lo sviluppo del progetto “Azioni intraprese per mantenere i risultati conseguiti sulla base di precedenti progetti finanziati da OTT” (codice progetto 14MO07)

Dal 27/02/2014 al 26/02/2015 - Azienda Ospedaliero-Universitaria Careggi (SSN), Largo Brambilla 3, 50134, Firenze: Contratto libero professionale di medico ematologo a tempo pieno presso la SOD Ematologia per lo sviluppo del progetto “Piano organizzativo Rete Trapianti CSE Toscana mediante la costituzione di un Coordinamento Regionale Trapianti CSE (CRTCSE)” (codice progetto “13MOAB”)

Dal 06/02/2012 al 05/12/2013 - Azienda Ospedaliero-Universitaria Careggi (SSN), Largo Brambilla 3, 50134, Firenze: Inserimento in attività assistenziale (servizio dipendente) presso la SOD Ematologia, sul contratto in essere di ricercatore a tempo determinato, con profilo assistenziale a impegno orario di 33 ore settimanali (28 di assistenza e 5 di attività didattica, 100% dell’indennità ex D. Lgs. 517/99)

Dal 01/11/2008 al 05/12/2013 – Università degli Studi di Firenze (Altra Pubblica Amministrazione), Largo Brambilla 3, 50134, Firenze: Contratto di ricercatore a tempo determinato (contratto individuale di lavoro subordinato a tempo determinato) a tempo pieno per il progetto di ricerca “Clearance dei blasti periferici durante terapia di induzione in pazienti adulti affetti da Leucemia Mieloide Acuta”. Insegnamento di Ematologia presso le Scuole di Medicina, Infermiere, Biotecnologie dell'Università degli Studi di Firenze.

Dal gennaio 2007 al gennaio 2012 - Laboratorio Analisi Dr Settimelli srl, Via della Querciola 12, Sesto Fiorentino (FI): contratto libero-professionale di medico ematologo per consulenze cito-morfologiche.

Dal 01/09/2004 al 28/02/2008 – Istituto Fiorentino di Cura e Assistenza, case di cura private convenzionate con SSN Villa Glicini (Via del Pergolino 4/6, Firenze) e Villa Santa Chiara (P.zza Indipendenza, Firenze); contratto libero-professionale di medico per lo svolgimento di attività di guardia medica nei notturni e festivi.

Altre attività svolte:

Aprile 2024: Principal Investigator del progetto “APL-like subset within NPM1-mutated acute myeloid leukemia: a distinct phenotypic signature correlating with early-onset vascular complications” risultato meritevole di finanziamento nell’ambito del Bando per le Idee 2024 promosso dal gruppo GIMEMA.

Novembre 2023: Segreteria scientifica e chairman al III congresso annuale dell’Associazione RIMA (Rete Italiana Mastocitosi), sede Firenze, Grand Hotel Baglioni

Settembre 2021: Segreteria scientifica, chairman e relatore al Preceptorship internazionale “Systemic mastocytosis: a multidisciplinary approach”, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze.

Dal 01/01/2014 a 11/12/2016 - Università degli Studi di Firenze (Altra Pubblica Amministrazione), Largo Brambilla 3, 50134, Firenze: Assegno di ricerca a carattere assistenziale presso la SOD Ematologia (Responsabile Prof. A Bosi). Titolo del progetto di ricerca: “Studio della displasia multi-lineare tramite citometria a flusso nella leucemia mieloide acuta”

Dal 02/03/2008 al 31/05/2008 - Stage della durata di 3 mesi presso il Servizio Generale di Citometria dell’Università di Salamanca, Spagna, diretto dal Prof. Alberto Orfao, in cui sono state perfezionate le conoscenze in varie tecniche di citometria di flusso su leucemie acute, sindromi mielodisplastiche, mieloma multiplo e sindromi linfoproliferative croniche; durante suddetto periodo, frequenza dei seminari del corso di Dottorato in Citometria di Flusso.

Dal 01/11/2006 al 30/10/2008 - Università degli Studi di Firenze (Altra Pubblica Amministrazione), Largo Brambilla 3, 50134, Firenze: Assegno di ricerca a carattere assistenziale presso la SOD Ematologia (Responsabile Prof. A Bosi). Titolo del progetto di ricerca “Studio citofluorimetrico dei compartimenti staminali normale e leucemico in pazienti affetti da Leucemia Mieloide Acuta e possibili applicazioni nella valutazione della malattia minima residua”.

Nelle varie esperienze professionali, dal 2006 a oggi, attività clinica presso Degenza Onco-Ematologica, Trapianto di Midollo Osseo, e Centro Ricerca e Innovazione nelle Malattie Mieloproliferative (CRIMM) con acquisizione di consolidata esperienza nella diagnostica e nella gestione clinica dei pazienti affetti da neoplasie ematologiche, anche nell’ambito di protocolli clinici sperimentali di varie fasi (dalla 1 alla 3). Dal 2008 al 2016, responsabile del Laboratorio di Citometria, da cui consolidata esperienza nella diagnostica (inclusiva della valutazione di preparati cito-morfologici) e nel monitoraggio della malattia minima residua delle neoplasie ematologiche (e in particolare leucemie acute, sindromi linfoproliferative, sindromi mielodisplastiche), esperienza comprovata da controlli esterni di qualità UK Neqas ed EuroFlow.

Attività di ricerca:

2021: conseguimento abilitazione scientifica nazionale a professore II fascia Bando D.D. 2175/2018 Settore concorsuale 06/D3 Malattie del sangue, Oncologia e Reumatologia.

2021: Correlatore tesi di Scuola di Specializzazione in Ematologia dal titolo “Hereditary Alpha Tryptasemia in Mastocytosis: analysis of a series of 444 patients”

Correlatore tesi Laurea Magistrale (LM-41) in Medicina e Chirurgia dal titolo “Regimi a base di Venetoclax per la leucemia mieloide acuta recidivante/refrattaria. Esperienza su 47 pazienti”.

2021: Membro del writing committee e co-Principal Investigator per l'ideazione, la stesura e la conduzione del protocollo clinico prospettico multicentrico ENABLE nelle leucemie mieloidi acute secondarie a neoplasia mieloproliferativa (EudraCT number 2020-006114-20) nell'ambito del Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA AML 2420).

2021: Membro della commissione Premio Francesca Martini per una Tesi Sperimentale in Oncoematologia 2021 promosso dalla associazione NANA ONLUS.

2020: Qualifica di Cultore della Materia di Ematologia, settore MED/15, presso l’Università degli Studi di Firenze.

2016-2020: Principal Investigator per la conduzione del progetto di ricerca “Peripheral blast clearance analysis during induction treatment in patients with acute myeloid leukemia” (project code GR-2013-02358238) finanziato da parte del Ministero della Salute (Bando Ricerca Finalizzata 2013 – Sezione Giovani Ricercatori). Il progetto aveva in precedenza ottenuto finanziamenti da parte di Istituto Toscano Tumori, Regione Toscana ed Ente Cassa di Risparmio Firenze ed è stato inserito nel contesto del protocollo multicentrico di trattamento AML 02-06 del Northern Italy Leukemia Group (NILG).

2019: Membro del gruppo di lavoro per il progetto AML Academy promosso da Accademia Nazionale di Medicina per la divulgazione di nuove evidenze scientifiche e della loro applicazione nella pratica clinica nell’ambito della leucemia mieloide acuta (https://amla.accmed.org/board)

2019: Membro del writing committee e co-Principal Investigator per l'ideazione, la stesura e la conduzione del protocollo clinico prospettico multicentrico AMELIORATE nella leucemia mieloide acuta (codice EudraCT 2019-003936-21) nell'ambito del Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA AML 1919)

2018: Membro del core team della Unità di Ricerca della Università di Firenze nell'ambito del gruppo MYeloid NEoplasms VentuRe AIRC (MYNERVA) per la conduzione del programma di ricerca “Actionable targets in clonal progression and systemic spreading of myeloid neoplasms” supportato da Associazione Italiana Ricerca sul Cancro (AIRC) - Programma di ricerca 5 per Mille 2018 (codice ID 21267)

2014-2018: Responsabile scientifico per l’Unità SOD Ematologia della AOU Careggi per la conduzione del progetto di ricerca: “Detecting copy number variants from whole-exome sequencing data applied to acute myeloid leukemia” (project CUP code D12I14000580001) finanziato da parte del Ministero della Salute (Bando Ricerca Finalizzata 2012 – Sezione Giovani Ricercatori).

2013: Correlatore tesi Laurea Magistrale (LM-41) in Medicina e Chirurgia dal titolo “Studio sistematico della malattia minima residua nelle leucemie mieloidi acute: dalla tecnica all’applicazione clinica”

2012-2016: Ideazione, progettazione e conduzione del progetto “Monitoring of chimerism on sorted peripheral CD34+ cells in patients with acute leukemia receiving allogeneic bone marrow transplant”, finanziato da parte di Ministero della Salute e Regione Toscana (Bando Ricerca Finalizzata 2009; project CUP code D11J09000190003).

2007-2014: Membro del Comitato Scientifico del Northern Italy Leukemia Group (NILG), in particolare per la stesura e conduzione del protocollo clinico NILG 02-06 nell'ambito della leucemia mieloide acuta (www.clinicaltrials.gov ID #NCT00495287)

2015-2017: Membro del panel di esperti del Gruppo Italiano Citometria (GIC) per il progetto “Acute Leukemias immunophenotyping by flow cytometry: methods and clinical value”.

Revisore di articoli per le riviste scientifiche Blood, Haematologica, Experimental Hematology, Leukemia Research, Journal of Clinical Laboratory Analysis, Journal of Hematology and Oncology. Membro del board editoriale della rivista Journal of Blood Disorders and Medicine (ISSN-2470-9956).

Relazioni a congressi come primo autore:

Relatore della proposta di studio “Acute leukemias arising in MPN” al Simposio European Leukemia Net in data 18/04/2023 presso Mannheim, Germania

Comunicazione orale selezionata come primo autore dal titolo “Third generation sequencing of normal karyotype acute myeloid leukemia: identification of a disease subset with unfavorable prognosis. A MYNERVA-GIMEMA collaborative study. Autori: Mannelli F, Bartalucci N, Romagnoli S, Gianfaldoni G, Piccini M, Scappini B, Pelo E, Pancani F, Vanderwert F, Maccari C, Signori L, Piciocchi A, Crea E, Fazi P, Vignetti M, Venditti A, Buccisano F, Voso MT, Amadori S, Guglielmelli P, Vannucchi AM. Congresso: XVII Congresso Nazionale Società Italiana Ematologia Sperimentale 2022. Sede: Roma, Italy. Data: 31/3-2/4/2022

Comunicazione orale selezionata come primo autore dal titolo “Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in myelofibrosis”. Autori: Mannelli F, Bencini S, Coltro G, Loscocco G, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Vannucchi AM, Guglielmelli P. Congresso: XVII Congresso Nazionale Società Italiana Ematologia Sperimentale 2022. Sede: Roma, Italy. Data: 31/3-2/4/2022

Relatore nella sessione educazionale “Sindromi ipereosinofile e mastocitosi” con relazione dal titolo “The treatment of systemic mastocytosis and eosinophilic disorders: from supportive to targeted” al 47° Congresso Nazionale della Società Italiana Ematologia 2019. Sede: Roma. Data: 7-9/10/2019

Comunicazione orale come primo autore dal titolo “Early peripheral blast cell clearance predicts minimal residual disease status after induction in acute myeloid leukemia”. Autori: Mannelli F, Gianfaldoni G, Cutini I, Bencini S, Bonetti MI, Piccini M, Scappini B, Ponziani V, Pancani F, Bosi A Rivista scientifica: HAEMATOLOGICA Volume: 100 Supplement: 3 Pages: 42. Congresso: 45° Congresso della Società Italiana di Ematologia. Sede: Firenze, ITALY; Data: 4-7/10/2015

Comunicazione orale come primo autore dal titolo “Multi-lineage dysplasia as assessed by immuno-phenotype has no impact on clinical-biologic features and outcome of acute myeloid leukemia with mutated nucleophosmin (NPM1)”. Autori: Mannelli F, Bencini S, Gianfaldoni G, Ponziani V, Cutini I, Scappini B, Pancani F, Biagiotti C, Bonetti MI, Longo G, Bosi A. Atti congresso. Congresso: 31° Congresso della Società Italiana di Citometria. Sede: Lucca, ITALY; Data: 8-11/10/2013

Relatore nella sessione educazionale “Malattia Minima Residua” con relazione dal titolo “MRD in citometria a flusso” al Congresso Nazionale del Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Sede: Firenze, Italy. Data: 5-6/5/2011

Comunicazione orale come primo autore dal titolo “The phenotypic profile of whole bone marrow cells provides clustering of genetic subtypes in acute myeloid leukemia”. Autori: Mannelli F, Bencini S, Cutini I, Gianfaldoni G, Benelli M, Magi A, Pancani F, Ponziani V, Biagiotti C, Scappini B, Bosi A. Rivista scientifica: CYTOMETRY PART B-CLINICAL CYTOMETRY Volume: 80B Issue: 6 Pages: 397-397. Congresso: 11° Annual Meeting of the European Society for Clinical Cell Analysis (ESCCA). Sede: Dublin, IRELAND; Data: 14-17/09/2011

Premi:

Premio GIC – Società Italiana di Citometria – 2013: menzione speciale per l’articolo “CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia”

Capitoli di libri:

Autore del capitolo sulle Leucemie Acute per il volume “Manuale di Malattie del Sangue” ed. Elsevier anno 2012.

Autore del capitolo “Immunophenotyping of acute leukemias – from biology to clinical application” ed. Intech anno 2016

Pubblicazioni:

Titolo: The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. Autori: Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Rivista: Am J Hematol. 2023 Oct 17. doi: 10.1002/ajh.27136. Online ahead of print. PMID: 37846894

Titolo: A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Autori: Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, Hanson CA, Ketterling RP, De Stefano V, Carobbio A, Barbui T, Guglielmelli P, Gangat N, Vannucchi AM. Rivista: Am J Hematol. 2023 Sep 4. doi: 10.1002/ajh.27079. Online ahead of print. PMID: 37665758

Titolo: Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement. Autori: Loscocco GG, Ascani S, Mannelli F, Zanelli M, Rotunno G, Santi R, Vannucchi AM. Rivista: Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026. Online ahead of print. PMID: 37435901 No abstract available.

Titolo: Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. Autori: Calabresi L, Carretta C, Romagnoli S, Rotunno G, Parenti S, Bertesi M, Bartalucci N, Rontauroli S, Chiereghin C, Castellano S, Gentili G, Maccari C, Vanderwert F, Mannelli F, Della Porta M, Manfredini R, Vannucchi AM, Guglielmelli P. Rivista: Am J Hematol. 2023 Oct;98(10):1520-1531. doi: 10.1002/ajh.27013. Epub 2023 Jul 3. PMID: 37399248

Titolo: Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia. Autori: Mannelli F, Piccini M, Bencini S, Gianfaldoni G, Peruzzi B, Caporale R, Scappini B, Fasano L, Quinti E, Ciolli G, Pasquini A, Crupi F, Pilerci S, Pancani F, Signori L, Tarantino D, Maccari C, Paradiso V, Annunziato F, Guglielmelli P, Vannucchi AM. Rivista: Haematologica. 2023 Jun 22. doi: 10.3324/haematol.2023.283196. Online ahead of print. PMID: 37345475 Free article.

Titolo: The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Autori: Piccini M, Mannelli F, Coltro G. Rivista: Bioengineering (Basel). 2023 May 13;10(5):591. doi: 10.3390/bioengineering10050591. PMID: 37237661 Free PMC article. Review.

Titolo: Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project. Autori: Coltro G, Sant'Antonio E, Palumbo GA, Mannelli F, De Stefano V, Ruggeri M, Elli EM, Zanotti R, Borsani O, Bertozzi I, Duminuco A, Betti S, Carli G, Cavalca F, Tanasi I, Rumi E, Randi ML, Garibaldi B, Loscocco GG, Guglielmelli P, Vannucchi AM. Rivista: Cancer Med. 2023 Jan 27. doi: 10.1002/cam4.5618. PMID: 36708083

Titolo: ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. Autori: Mannelli F, Guglielmelli P, Fazi P, Crea E, Piciocchi A, Vignetti M, Amadori S, Pane F, Venditti A, Vannucchi AM. Rivista: Future Oncol. 2023 Jan 18. doi: 10.2217/fon-2022-0512. PMID: 36651780

Titolo: Diagnostic and therapeutic challenges in mast cell sarcoma. Autori: Mannelli F, Gesullo F, Mannarelli C, Vanderwert F, Lazzi S, Mungai F, Berti V, Santi R, Guglielmelli P, Vannucchi AM. Rivista: Am J Hematol. 2023 Mar;98(3):529-532. doi: 0.1002/ajh.26804. PMID: 36464921

Titolo: Disease correlates and clinical relevance of Hereditary Alpha-Tryptasemia in patients with Systemic Mastocytosis. Autori: Sordi B, Vanderwert F, Crupi F, Gesullo F, Zanotti R, Bonadonna P, Crosera L, Elena C, Fiorelli N, Ferrari J, Grifoni F, Sciumè M, Parente R, Triggiani M, Palterer B, Mecheri V, Almerigogna F, Santi R, Di Medio L, Brandi ML Iorno ML, Ciardetti I, Bencini S, Annunziato F, Mannarelli C, Pieri L, Guglielmelli P, Mannelli F*, Vannucchi AM* (*co-last authors). Rivista: Journal of Clin Immunol and Allergy 2022 (in press)

Titolo: Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Autori: Coltro G, Mannelli F, Loscocco GG, Mannarelli C, Rotunno G, Maccari C, Pancani F, Atanasio A, Vannucchi AM, Guglielmelli P. Rivista: Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6. PMID: 35961958

Titolo: Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management. Autori: Crupi F, Sordi B, Vanderwert F, Gesullo F, Amorosi A, Mannelli F, Santi R. Rivista: Int J Mol Sci. 2022 Aug 7;23(15):8772. doi: 0.3390/ijms23158772. PMID: 35955907

Titolo: SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. Autori: Loscocco GG, Guglielmelli P, Mannelli F, Mora B, Mannarelli C, Rotunno G, Pancani F, Maccari C, Bartalucci N, Romagnoli S, Coltro G, Passamonti F, Vannucchi AM. Rivista: Am J Hematol. 2022 Sep;97(9):E347-E349; doi: 10.1002/ajh.26648. Epub 2022 Jul 15. PMID: 35796725

Titolo: Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. Autori: Loscocco GG, Santi R, Carrai V, Coltro G, Mannelli F, Guglielmelli P, Vannucchi AM. Rivista: Int J Lab Hematol. 2022 May 27. doi: 10.1111/ijlh.13902. Epub ahead of print. PMID: 35622069.

Titolo: Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. Autori: Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Guglielmelli P, Vannucchi AM. Rivista: Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31. PMID: 35338671

Titolo: ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Autori: Guglielmelli P, Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, Maccari C, Paoli C, Romagnoli S, Bartalucci N, Vannucchi AM Rivista: Blood Adv. 2022 May 10;6(9):2927-2931. doi: 10.1182/bloodadvances.2021006350. PMID: 35020812

Titolo: JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis Autori: Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, Coltro G, Betti S, Maccari C, Ceglie S, Chiusolo P, Paoli C, Barbui T, Tefferi A, De Stefano V, and Vannucchi AM Rivista: Blood Cancer Journal 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6.

Titolo: Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. Autori: Romagnoli S, Bartalucci N, Gesullo F, Balliu M, Bonifacio S, Fernandez AGL, Mannelli F, Bolognini D, Pelo E, Mecucci C, Guglielmelli P and Vannucchi AM. Rivista: Biomarker Research 2021; 9(83):1-4; doi: 10.1186/s40364-021-00337-1

Titolo: Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of ERNEST Study. Autori: Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larran A, Andreasson BI, Vannucchi AMM, Barbui T. Rivista: Blood Adv. 2021 Nov 9:bloodadvances.2021006006. doi: 10.1182/bloodadvances.2021006006.

Titolo: AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. Autori: Mannelli F, Gianfaldoni G, Guglielmelli P, Buccisano F, Caporale R, Chiarini M, Rossi G, Venditti A, Fazi P, Crea E, Piciocchi A, Voso MT, Vignetti M, Amadori S, Vannucchi AM. Rivista: Future Oncol. 2021 Oct;17(29):3787-3796. doi: 10.2217/fon-2021-0388. Epub 2021 Jul 13. PMID: 34254530

Titolo: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Autori: Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK. Rivista: Leukemia. 2021 May 20. doi: 10.1038/s41375-021-01261-x. PMID: 34017073

Titolo: Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Autori: Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Rivista: Am J Hematol. 2021 Apr 12. doi: 10.1002/ajh.26186. PMID: 33844862

Titolo: Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. Autori: Loscocco GG, Antonioli E, Romano I, Vergoni F, Rotunno G, Mannelli F, Guglielmelli P, Vannucchi AM. Rivista: Am J Hematol. 2021 Jun 1;96(6):749-754. doi: 10.1002/ajh.26153. Epub 2021 Mar 29. PMID: 33719069

Titolo: Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. Autori: Tanasi I, Bonifacio M, Pizzolato M, Irene Grifoni F, Sciumè M, Elena C, Benvenuti P, Mannelli F, Parente R, Schena D, Scaffidi L, Bonadonna P, Papayannidis C, Rondoni M, Criscuolo M, Vannucchi AM, Triggiani M, Martinelli G, Krampera M, Zanotti R. Rivista: Br J Haematol. 2021 May;193(4):845-848. doi: 10.1111/bjh.17405. Epub 2021 Mar 22. PMID: 33754335

Titolo: Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease. Autori: Mannelli F. Rivista: J Clin Med. 2021 Jan 23;10(3):436. doi: 10.3390/jcm10030436. PMID: 33498691 Free PMC article. Review.

Titolo: BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Autori: Loscocco GG, Rotunno G, Mannelli L, Mannelli F, Vergoni F, Guglielmelli P, Vannucchi AM. Rivista: Tumori. 2021 Jan 12:300891620986621. doi: 10.1177/0300891620986621. PMID: 33430710

Titolo: Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature. Autori: Berti PP, Pirillo V, Rizzo P, Ria A, Mannelli F, Broger M. Rivista: Br J Neurosurg. 2020 Nov 28:1-3. doi: 10.1080/02688697.2020.1849549. PMID: 33249871

Titolo: Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis. Autori: Mannelli F. Rivista: Ann Hematol. 2020 Nov 6:1-8. doi: 10.1007/s00277-020-04323-9. PMID: 33156374

Titolo: Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. Autori: Mannelli F, Bencini S, Piccini M, Gianfaldoni G, Bonetti MI, Peruzzi B, Caporale R, Scappini B, Pancani F, Ponziani V, Signori L, Zizza M, Annunziato F, Bosi A. Rivista scientifica: Cancers (Basel). 2020 Oct 30;12(11):E3196. doi: 10.3390/cancers12113196. PMID: 33143086

Titolo: Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Autori: Caprioli C, Lussana F, Salmoiraghi S, Cavagna R, Buklijas K, Elidi L, Zanghi' P, Michelato A, Delaini F, Oldani E, Intermesoli T, Grassi A, Gianfaldoni G, Mannelli F, Ferrero D, Audisio E, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Cavattoni I, Tajana M, Scattolin AM, Mattei D, Corradini P, Campiotti L, Ciceri F, Bernardi M, Todisco E, Cortelezzi A, Falini B, Pavoni C, Bassan R, Spinelli O, Rambaldi A. Rivista scientifica: Haematologica. 2020 Aug 27:haematol.2020.252825. doi: 10.3324/haematol.2020.252825.

Titolo: Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML. Autori: Mannelli F*, Gianfaldoni G*, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A. (*co-first authors) Rivista scientifica: Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25942.

Titolo: A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. Autori: Loscocco GG, Mannelli F, Mannelli L, Vergoni F, Gesullo F, Rotunno G, Guglielmelli P, Vannucchi AM. Rivista scientifica: Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.

Titolo: Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Autori: Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T. Rivista scientifica: Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2.

Titolo: Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature Autori: Coltro G, Mannelli F, Vergoni F, Santi R, Massi D, Siliani LM, Marzullo A, Bonifacio S, Pelo E, Pacilli A, Paoli C, Franci A, Calabresi L, Bosi A, Vannucchi AM, Guglielmelli P. Rivista scientifica: Clin Exp Med. 2020 May;20(2):313-320. doi: 10.1007/s10238-020-00616-5.

Titolo: Health technology assessment-based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. Autori: Gaipa G, Erba E, Danova M, Mazzini G, Venditti A, Buldini B, Specchia G, Maglia O, Kunkl A, Ciriello MM, Arpinati M, Mannelli F, Lanza F, Riccioni R, Pistotti V, Apolone G; Società Italiana di Citometria (GIC). Rivista scientifica: Tumori. 2020 Feb 14:300891620904412. doi: 10.1177/0300891620904412.

Titolo: Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Autori: Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Rivista scientifica: Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462.

Titolo: Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Autori: Gianfaldoni G*, Mannelli F*, Intermesoli T, Bencini S, Giupponi D, Farina G, Cutini I, Bonetti MI, Masciulli A, Audisio E, Ferrero D, Pavoni C, Scattolin AM, Bosi A, Rambaldi A, Bassan R. (*co-first authors) Rivista scientifica: Blood Adv. 2020 Jan 28;4(2):301-311. doi: 10.1182/bloodadvances.2019000406.

Titolo: Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Autori: Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Lurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM. Rivista scientifica: Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677.

Titolo: Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. Autori: Guglielmelli P, Pacilli A, Coltro G, Mannelli F, Mannelli L, Contini E, Rotunno G, Bartalucci N, Fiaccabrino S, Sordi B, Loscocco GG, Paoli C, Vannucchi AM. Rivista scientifica: Am J Hematol. 2019 Oct 29. doi: 10.1002/ajh.25668.

Titolo: Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Autori: Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, Bonifacio M, Parisi A, Gattei V, Zamò A, Mannelli F, García Montero AC, Zanotti R. Rivista scientifica: Hematol Oncol. 2019 Sep 16. doi: 10.1002/hon.2680. [Epub ahead of print]

Titolo: Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. Autori: Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM. Rivista scientifica: Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25555

Titolo: Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Autori: Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P. Rivista scientifica: Blood. 2019 May 10. pii: blood.2018879536. doi: 10.1182/blood.2018879536.

Titolo: Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. Autori: Mannelli F, Gesullo F, Rotunno G, Pacilli A, Bencini S, Annunziato F, Zanotti R, Scaffidi L, Giona F, Santopietro M, Grifoni F, Pieri L, Guglielmelli P, Vannucchi AM. Rivista scientifica: Am J Hematol. 2019 May 6. doi: 10.1002/ajh.25506

Titolo: Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Autori: Magi A, Bolognini D, Bartalucci N, Mingrino A, Semeraro R, Giovannini L, Bonifacio S, Parrini D, Pelo E, Mannelli F, Guglielmelli P, Vannucchi AM. Rivista scientifica: Bioinformatics. 2019 Apr 5. pii: btz241. doi: 10.1093/bioinformatics/btz241

Titolo: A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. Autori: Grifoni FI, Sciumè M, Pravettoni V, Ulivieri FM, Muratori S, Fracchiolla NS, Tagliaferri E, Gianelli U, Migliorini AC, Cro L, Pacilli A, Mannelli F, Baldini L. Rivista scientifica: Hematol Oncol. 2019 Apr;37(2):205-211 doi: 10.1002/hon.2605

Titolo: Validation of the Mayo alliance prognostic system for mastocytosis. Autori: Mannelli F, Gesullo F, Rotunno G, Pacilli A, Pieri L, Guglielmelli P, Vannucchi AM. Rivista scientifica: Blood Cancer J. 2019 Feb 11;9(2):18.

Titolo: Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. Autori: Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A. Rivista scientifica: J Blood Med. 2018 Dec 27;10:21-27.

Titolo: Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Autori: Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P. Rivista scientifica: Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x

Titolo: Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Autori: Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A. Rivista scientifica: Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245

Titolo: GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Autori: Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM. Rivista Scientifica: Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0107-z

Titolo: Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Autori: Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM. Rivista Scientifica: Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y

Titolo: MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Autori: Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. Rivista Scientifica: J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886

Titolo: A life-threatening ruxolitinib discontinuation syndrome. Autori: Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM. Rivista Scientifica: Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775

Titolo: CEBPA–double mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features Autori: Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AMG, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A Rivista Scientifica: Haematologica 2017; 102(3):529-540. doi: 10.3324/haematol.2016.151910

Titolo: Immunophenotyping of acute leukemias: insight into prognosis since the outset Autori: Mannelli F Rivista Scientifica: J Blood Dis Med 2016

Titolo: Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Autori: Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, Oldani E, Tosi M, Grassi A, Parolini M, Audisio E, Cattaneo C, Raimondi R, Angelucci E, Cavattoni IM, Scattolin AM, Cortelezzi A, Mannelli F, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Romani C, Bassan R, Rambaldi A. Rivista scientifica: Biol Blood Marrow Transplant. 2016 Aug 1. pii: S1083-8791(16)30257-9. doi: 10.1016/j.bbmt.2016.07.021

Titolo: Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biologic features and outcome of NPM1-mutated acute myeloid leukemia. Autori: Mannelli F, Ponziani V, Bonetti MI, Bencini S, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Rondelli T, Benelli M, Caporale R, Gelli AMG, Peruzzi B, Longo G, Bosi A. Rivista Scientifica: Exp Hematol. 2015;43(10):869. doi: 10.1016/j.exphem.2015.06.003

Titolo: CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Autori: Mannelli F, Cutini I, Gianfaldoni G, Bencini S, Scappini B, Pancani F, Ponziani V, Bonetti MI, Biagiotti C, Longo G, Bosi A. Rivista Scientifica: 2 2014;86:340. doi: 10.1002/cyto.b.21156

Titolo: Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. Autori: Peruzzi B, Cutini I, Gelli AM, Rondelli T, Statello M, Bencini S, Mannelli F, Caporale R, Bosi A, Fanelli A. Rivista scientifica: Int Med Case Rep J. 2013;6:77. doi: 10.2147/IMCRJ.S49278

Titolo: Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: a retrospective Italian multicentric study. Autori: Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Gaidano G, Pica G, Onida F, Cattaneo C, Piccaluga PP, Rodeghiero F, Todisco E, Leone G, Pileri S, Amadori S, Facchetti F for GIMEMA-ALWP* (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Rivista scientifica: Haematologica 2012; 98(2): 239. doi: 10.3324/haematol.2012.072645

Titolo: Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Autori: Benevolo G, Stacchini A, Spina M, Arras M, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Ferreri A, Franceschetti S, Godio L, Mannelli F, Pavone L, Pioltelli P, Vitolo U, Pogliani EM. Rivista scientifica: Blood 2012; 120(16): 3222. doi: 10.1182/blood-2012-04-423095

Titolo: A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI-deficiency in Paroxysmal Nocturnal Hemoglobinuria. Autori: Mannelli F, Bencini S, Peruzzi B, Cutini I, Sanna A, Benelli M, Magi A, Gianfaldoni G, Rotunno G, Carrai V, Gelli AMG, Valle V, Santini V, Notaro R, Luzzatto L, Bosi A. Rivista scientifica: Cytometry Part B 2013;84(2):71. doi: 10.1002/cyto.b.21064

Titolo: Cytarabine and Clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Autori: Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Angelucci E, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Bosi A. Rivista scientifica: Am J Hematol 2012; 87(12): 1047. doi: 10.1002/ajh.23308

Titolo: CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. Autori: Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, Romani C, Ciceri F, Corti C, Scattolin A, Cortelezzi A, Mattei D, Audisio E, Spinelli O, Oldani E, Bosi A, Rambaldi A, Bassan R. Rivista scientifica: Haematologica 2012; 97 (4): 568. doi: 10.3324/haematol.2011.054064

Titolo: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Autori: Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Rivista scientifica: Journal of Clinical Oncology 2010; 28 (22): 3644. doi: 10.1200/JCO.2010.28.1287

Titolo: Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease-free and overall survival in acute myeloid leukemia. Autori: Gianfaldoni G*, Mannelli F*, Ponziani V, Longo G, Bencini S, Bosi A and Vannucchi AM. (*co-first authors) Rivista scientifica: Haematologica 2010; 95 (5): 833. doi: 10.3324/haematol.2009.011908

Titolo: Atypical Acute Leukemia Early After Liver Transplantation. Autori: Mannelli F, De Simone P, Gianfaldoni G, Nozzoli C, Filipponi F and Bosi A. Rivista scientifica: Transplantation Proceedings 2009 (41): 3945. doi: 10.1016/j.transproceed.2009.06.194

Titolo: Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Autori: Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J and Paoletti F. Rivista scientifica: Experimental Hematology 2009; 37 (10): 1176. doi: 10.1016/j.exphem.2009.07.002

Titolo: Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. Autori: Gianfaldoni G*, Mannelli F*, Bencini S, Leoni F, Baldini S, Bosi A (*co-first authors) Rivista scientifica: Blood 2008; 111: 1746. doi: 10.1182/blood-2007-10-121103

Titolo: No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. Autori: Ponziani V, Mannelli F, Bartalucci N, Gianfaldoni G, Leoni F, Antonioli E, Guglielmelli P, Ciolli S, Bosi A, Vannucchi AM. Rivista scientifica: Leukemia 2008; 22 (3): 669. doi: 10.1038/sj.leu.2404938

Titolo: Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’ Tumor gene 1 (WT1). Autori: Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Busse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. Rivista scientifica: Stem Cells 2007; 25(1): 165. doi: 10.1634/stemcells.2006-0351

Titolo: The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Autori: Ponziani V, Gianfaldoni G, Mannelli F, Leoni F, Ciolli S, Guglielmelli P, Antonioli E, Longo G, Bosi A and Vannucchi AM. Rivista scientifica: Leukemia 2006; 1(4): 302. doi: 10.1038/sj.leu.2404368

Titolo: Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Autori: Gianfaldoni G, Mannelli F, Antonioli E, Vannucchi AM and Bosi A. Rivista scientifica: Br J Haematol. 2006 Jul;134(1): 54. doi: 10.1111/j.1365-2141.2006.06100.x

Titolo: Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Autori: Antonioli E, Nozzoli C, Gianfaldoni G, Mannelli F, Rossi S, Betti S, Bernardeschi P, Fiorentini G and Bosi A. Rivista scientifica: Ann Oncol 2005; 16(11): 1849. doi: 10.1093/annonc/mdi357

Titolo: Chronicrelapsing thrombotic thrombocytopenic purpura successfully treated with Rituximab: case report. Autori: Gianfaldoni G, Antonioli E, Mannelli F, Vannucchi AM and Bosi A. Rivista scientifica: Journal of Chemotherapy 2005; 17 (4): 449. doi: 10.1179/joc.2005.17.4.449

Francesco MANNELLI

Pubblicazioni

Legenda

Contributo su rivista |

Articolo su libro |

Libro |

Contributo in atti di convegno (proceeding) |

Brevetto |

Curatela | Altro

Altro |

Tesi di Dottorato

Guglielmelli, Paola; Mora, Barbara; Gesullo, Francesca; Mannelli, Francesco; Loscocco, Giuseppe Gaetano; Signori, Leonardo; Pessina, Chiara; Colugnat, Ilaria; Aquila, Raffaela; Balliu, Manjola; Maccari, Chiara; Romagnoli, Simone; Paoli, Chiara; Nacca, Elena; Fagiolo, Lorenzo; Maffioli, Margherita; Barbui, Tiziano; Passamonti, Francesco; Vannucchi, Alessandro M. (2024). Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 1550-1559, ISSN:0361-8609 DOI

Ciolli, Gaia; Pasquini, Andrea; Mannelli, Francesco; Scappini, Barbara; Gianfaldoni, Giacomo; Quinti, Elisa; Fasano, Laura; Caroprese, Jessica; Crupi, Francesca; Vannucchi, Alessandro Maria; Piccini, Matteo (2024). Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 15, pp. 0-0, ISSN:2040-6207 DOI

Coltro, Giacomo; Capecchi, Giulio; Maffioli, Margherita; Mannelli, Francesco; Mora, Barbara; Atanasio, Alessandro; Iurlo, Alessandra; Maccari, Chiara; Farina, Mirko; Nacca, Elena; Caramella, Marianna; Signori, Leonardo; Borella, Miriam; Bertù, Lorenza; Esposito, Maria; Guglielmelli, Paola; Passamonti, Francesco; Vannucchi, Alessandro Maria (2024). Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib. HAEMATOLOGICA, vol. 109, pp. 3398-3403, ISSN:1592-8721 DOI

Loscocco, Giuseppe G.; Rotunno, Giada; Mannelli, Francesco; Coltro, Giacomo; Gesullo, Francesca; Pancani, Fabiana; Signori, Leonardo; Maccari, Chiara; Esposito, Maria; Paoli, Chiara; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 68-78, ISSN:0361-8609 DOI

Loscocco, Giuseppe G.; Gesullo, Francesca; Capecchi, Giulio; Atanasio, Alessandro; Maccari, Chiara; Mannelli, Francesco; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. BLOOD CANCER JOURNAL, vol. 14, pp. 0-0, ISSN:2044-5385 DOI

Ciolli, Gaia; Piccini, Matteo; Mannelli, Francesco; Gianfaldoni, Giacomo; Scappini, Barbara; Fasano, Laura; Crupi, Francesca; Quinti, Elisa; Pasquini, Andrea; Caroprese, Jessica; Rotunno, Giada; Pancani, Fabiana; Signori, Leonardo; Maccari, Chiara; Vanderwert, Fiorenza I.; Guglielmelli, Paola; Vannucchi, Alessandro M. (2024). Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting. HAEMATOLOGICA, pp. 0-0, ISSN:1592-8721 DOI

Mannelli, Francesco; Piccini, Matteo; Bencini, Sara; Gianfaldoni, Giacomo; Peruzzi, Benedetta; Caporale, Roberto; Scappini, Barbara; Fasano, Laura; Quinti, Elisa; Ciolli, Gaia; Pasquini, Andrea; Crupi, Francesca; Pilerci, Sofia; Pancani, Fabiana; Signori, Leonardo; Tarantino, Danilo; Maccari, Chiara; Paradiso, Vivian; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia. HAEMATOLOGICA, pp. 0-0, ISSN:1592-8721 DOI

Berti, Pier Paolo; Pirillo, Vania; Rizzo, Paolo; Ria, Antonio; Mannelli, Francesco; Broger, Maximilian (2023). Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature. BRITISH JOURNAL OF NEUROSURGERY, vol. 37, pp. 1266-1268, ISSN:1360-046X DOI

Piccini, Matteo; Mannelli, Francesco; Coltro, Giacomo (2023). The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. BIOENGINEERING, vol. 10, pp. 591-591, ISSN:2306-5354 DOI

Mannelli, Francesco; Guglielmelli, Paola; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Vignetti, Marco; Amadori, Sergio; Pane, Fabrizio; Venditti, Adriano; Vannucchi, Alessandro M (2023). ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. FUTURE ONCOLOGY, vol. 19, pp. 103-111, ISSN:1744-8301 DOI

Mannelli, Francesco; Gesullo, Francesca; Mannarelli, Carmela; Vanderwert, Fiorenza; Lazzi, Stefano; Mungai, Francesco; Berti, Valentina; Santi, Raffaella; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Diagnostic and therapeutic challenges in mast cell sarcoma. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 529-532, ISSN:0361-8609 DOI

Sordi, Benedetta; Vanderwert, Fiorenza; Crupi, Francesca; Gesullo, Francesca; Zanotti, Roberta; Bonadonna, Patrizia; Crosera, Lara; Elena, Chiara; Fiorelli, Nicolas; Ferrari, Jacqueline; Grifoni, Federica; Sciumè, Mariarita; Parente, Roberta; Triggiani, Massimo; Palterer, Boaz; Mecheri, Valentina; Almerigogna, Fabio; Santi, Raffaella; Di Medio, Lisa; Brandi, Maria Luisa; Iorno, Maria Loredana; Ciardetti, Isabella; Bencini, Sara; Annunziato, Francesco; Mannarelli, Carmela; Pieri, Lisa; Guglielmelli, Paola; Mannelli, Francesco; Vannucchi, Alessandro M (2023). Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 151, pp. 485-493, ISSN:1097-6825 DOI

Calabresi, Laura; Carretta, Chiara; Romagnoli, Simone; Rotunno, Giada; Parenti, Sandra; Bertesi, Matteo; Bartalucci, Niccolò; Rontauroli, Sebastiano; Chiereghin, Chiara; Castellano, Sara; Gentili, Giulia; Maccari, Chiara; Vanderwert, Fiorenza; Mannelli, Francesco; Della Porta, Matteo; Manfredini, Rossella; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2023). Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 1520-1531, ISSN:0361-8609 DOI

Loscocco, Giuseppe G; Ascani, Stefano; Mannelli, Francesco; Zanelli, Magda; Rotunno, Giada; Santi, Raffaella; Vannucchi, Alessandro M (2023). Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement. AMERICAN JOURNAL OF HEMATOLOGY, pp. 1-4, ISSN:0361-8609 DOI

Mannelli, Francesco; Crupi, Francesca; Zanotti, Roberta; Pagano, Livio; Rapezzi, Davide; Tanasi, Ilaria; Criscuolo, Marianna; Bonifacio, Massimiliano; Fresa, Alberto; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis. THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 14, pp. 1-14, ISSN:2040-6207 DOI

Tefferi, Ayalew; Loscocco, Giuseppe G; Farrukh, Faiqa; Szuber, Natasha; Mannelli, Francesco; Pardanani, Animesh; Hanson, Curtis A; Ketterling, Rhett P; De Stefano, Valerio; Carobbio, Alessandra; Barbui, Tiziano; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M (2023). A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. AMERICAN JOURNAL OF HEMATOLOGY, pp. 0-0, ISSN:0361-8609 DOI

Coltro, Giacomo; Sant'Antonio, Emanuela; Palumbo, Giuseppe A; Mannelli, Francesco; De Stefano, Valerio; Ruggeri, Marco; Elli, Elena M; Zanotti, Roberta; Borsani, Oscar; Bertozzi, Irene; Duminuco, Andrea; Betti, Silvia; Carli, Giuseppe; Cavalca, Fabrizio; Tanasi, Ilaria; Rumi, Elisa; Randi, Maria L; Garibaldi, Bruno; Loscocco, Giuseppe G; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project. CANCER MEDICINE, vol. 12, pp. 8166-8171, ISSN:2045-7634 DOI

Mannelli, Francesco; Bencini, Sara; Coltro, Giacomo; Loscocco, Giuseppe G; Peruzzi, Benedetta; Rotunno, Giada; Maccari, Chiara; Gesullo, Francesca; Borella, Miriam; Paoli, Chiara; Caporale, Roberto; Mannarelli, Carmela; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. 846-855, ISSN:0361-8609 DOI

Loscocco, Giuseppe G; Santi, Raffaella; Carrai, Valentina; Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, pp. 1-2, ISSN:1751-5521 DOI

Crupi, Francesca; Sordi, Benedetta; Vanderwert, Fiorenza; Gesullo, Francesca; Amorosi, Andrea; Mannelli, Francesco; Santi, Raffaella (2022). Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 23, pp. 0-0, ISSN:1422-0067 DOI

Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM (2022). Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis. In: American Society of Hematology (ASH) 2022, Blood, pp. 832-833. DOI

Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M (2022). SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E347-E349, ISSN:1096-8652 DOI

Loscocco GG, Santi R, Mannarelli C, Mannelli F, Gesullo F, Coltro G, Guglielmelli P, Gianelli U, Vannucchi AM (2022). Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1%. In: American Society of Hematology (ASH) 2022, Blood, pp. 9714-9716. DOI

Coltro, Giacomo; Mannelli, Francesco; Loscocco, Giuseppe Gaetano; Mannarelli, Carmela; Rotunno, Giada; Maccari, Chiara; Pancani, Fabiana; Atanasio, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. BLOOD CANCER JOURNAL, vol. 12, pp. 1-7, ISSN:2044-5385 DOI

Guglielmelli P.; Ghirardi A.; Carobbio A.; Masciulli A.; Maccari C.; Mora B.; Rumi E.; Triguero A.; Finazzi M.C.; Pettersson H.; Paoli C.; Mannelli F.; Vanni D.; Rambaldi A.; Passamonti F.; Alvarez-Larran A.; Andreasson B.; Vannucchi A.M.; Barbui T. (2022). Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study. BLOOD ADVANCES, vol. 6, pp. 373-375, ISSN:2473-9529 DOI

Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. BLOOD ADVANCES, vol. 6, pp. 2927-2931, ISSN:2473-9537 DOI

Cervantes F.; Ross D.M.; Radinoff A.; Palandri F.; Myasnikov A.; Vannucchi A.M.; Zachee P.; Gisslinger H.; Komatsu N.; Foltz L.; Mannelli F.; Passamonti F.; Gilotti G.; Sadek I.; Tiwari R.; Zor E.; Al-Ali H.K. (2021). Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. LEUKEMIA, vol. 35, pp. 3455-3465, ISSN:0887-6924 DOI

Romagnoli S.; Bartalucci N.; Gesullo F.; Balliu M.; Bonifacio S.; Fernandez A.G.L.; Mannelli F.; Bolognini D.; Pelo E.; Mecucci C.; Guglielmelli P.; Vannucchi A.M. (2021). Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. BIOMARKER RESEARCH, vol. 9, pp. 83-86, ISSN:2050-7771 DOI

Gangat N.; Guglielmelli P.; Szuber N.; Begna K.H.; Patnaik M.M.; Litzow M.R.; Al-Kali A.; Foran J.M.; Palmer J.M.; Alkhateeb H.; Elliott M.A.; Hanson C.A.; Pardanani A.; Mannelli F.; Vannucchi A.M.; Tefferi A. (2021). Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 781-789, ISSN:0361-8609 DOI

Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L. (2021). Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. LEUKEMIA, pp. 1121-1133, ISSN:0887-6924 DOI

Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria (2021). AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial. FUTURE ONCOLOGY, vol. 17, pp. 3787-3796, ISSN:1479-6694 DOI

Loscocco G.G.; Antonioli E.; Romano I.; Vergoni F.; Rotunno G.; Mannelli F.; Guglielmelli P.; Vannucchi A.M. (2021). Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, pp. 749-754, ISSN:0361-8609 DOI

Tanasi, Ilaria; Bonifacio, Massimiliano; Pizzolato, Miriam; Irene Grifoni, Federica; Sciumè, Mariarita; Elena, Chiara; Benvenuti, Pietro; Mannelli, Francesco; Parente, Roberta; Schena, Donatella; Scaffidi, Luigi; Bonadonna, Patrizia; Papayannidis, Cristina; Rondoni, Michela; Criscuolo, Marianna; Vannucchi, Alessandro M.; Triggiani, Massimo; Martinelli, Giovanni; Krampera, Mauro; Zanotti, Roberta (2021). Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, pp. 845-848, ISSN:0007-1048 DOI

Cervantes, Francisco; Ross, David M; Radinoff, Atanas; Palandri, Francesca; Myasnikov, Alexandr; Vannucchi, Alessandro M; Zachee, Pierre; Gisslinger, Heinz; Komatsu, Norio; Foltz, Lynda; Mannelli, Francesco; Passamonti, Francesco; Gilotti, Geralyn; Sadek, Islam; Tiwari, Ranjan; Zor, Evren; Al-Ali, Haifa Kathrin (2021). Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. LEUKEMIA, vol. 35, pp. 3626-3626, ISSN:0887-6924 DOI

Loscocco G.G.; Rotunno G.; Mannelli L.; Mannelli F.; Vergoni F.; Guglielmelli P.; Vannucchi A.M. (2021). BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. TUMORI, vol. 107, pp. NP28-NP32, ISSN:0300-8916 DOI

Vanderwert, Fiorenza Irushani; Sordi, Benedetta; Mannelli, Francesco; Palterer, Boaz; Gesullo, Francesca; Mecheri, Valentina; Santi, Raffaella; Mannarelli, Carmela; Crupi, Francesca; Zanotti, Roberta; Grifoni, Federica Irene; Elena, Chiara; Parente, Roberta; Triggiani, Massimo; Lisa, Pieri; Almerigogna, Fabio; Guglielmelli, Paola; Vannucchi, Alessandro (2021). Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. BLOOD, vol. 138, pp. 1500-1502, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Gianfaldoni, Giacomo; Mannelli, Francesco; Intermesoli, Tamara; Bencini, Sara; Giupponi, Damiano; Farina, Giorgio; Cutini, Ilaria; Bonetti, Maria Ida; Masciulli, Arianna; Audisio, Ernesta; Ferrero, Dario; Pavoni, Chiara; Scattolin, Anna Maria; Bosi, Alberto; Rambaldi, Alessandro; Bassan, Renato (2020). Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. BLOOD ADVANCES, vol. 4, pp. 301-311-311, ISSN:2473-9529 DOI

Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. (2020). Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E23-E26, ISSN:0361-8609 DOI

Guglielmelli P.; Carobbio A.; Rumi E.; De Stefano V.; Mannelli L.; Mannelli F.; Rotunno G.; Coltro G.; Betti S.; Cavalloni C.; Finazzi M.C.; Thiele J.; Cazzola M.; Vannucchi A.M.; Barbui T. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. BLOOD CANCER JOURNAL, vol. 10, pp. 21-28, ISSN:2044-5385 DOI

Coltro, Giacomo; Mannelli, Francesco; Vergoni, Federica; Santi, Raffaella; Massi, Daniela; Siliani, Luisa Margherita; Marzullo, Antonella; Bonifacio, Stefania; Pelo, Elisabetta; Pacilli, Annalisa; Paoli, Chiara; Franci, Annalisa; Calabresi, Laura; Bosi, Alberto; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. CLINICAL AND EXPERIMENTAL MEDICINE, pp. 203-210, ISSN:1591-8890 DOI

Mannelli, Francesco; Gianfaldoni, Giacomo; Bencini, Sara; Piccini, Matteo; Cutini, Ilaria; Bonetti, Maria Ida; Scappini, Barbara; Pancani, Fabiana; Ponziani, Vanessa; Chiarini, Marco; Borlenghi, Erika; Bassan, Renato; Rossi, Giuseppe; Bosi, Alberto (2020). Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML. AMERICAN JOURNAL OF HEMATOLOGY, pp. 25-30, ISSN:0361-8609 DOI

Sant'Antonio E.; Guglielmelli P.; Pieri L.; Primignani M.; Randi M.L.; Santarossa C.; Rumi E.; Cervantes F.; Delaini F.; Carobbio A.; Betti S.; Rossi E.; Lavi N.; Harrison C.N.; Curto-Garcia N.; Gisslinger H.; Gisslinger B.; Specchia G.; Ricco A.; Vianelli N.; Polverelli N.; Koren-Michowitz M.; Ruggeri M.; Girodon F.; Ellis M.; Iurlo A.; Mannelli F.; Mannelli L.; Sordi B.; Loscocco G.G.; Cazzola M.; De Stefano V.; Barbui T.; Tefferi A.; Vannucchi A.M. (2020). Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. 156-166, ISSN:0361-8609 DOI

Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M. (2020). A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. 1622-1624, ISSN:0361-8609 DOI

Mannelli F.; Gesullo F.; Rotunno G.; Pacilli A.; Bencini S.; Annunziato F.; Zanotti R.; Scaffidi L.; Giona F.; Santopietro M.; Grifoni F.; Pieri L.; Guglielmelli P.; Vannucchi A.M. (2019). Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. 845-852, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Rotunno G.; Mannarelli C.; Brogi G.; Pacilli A.; Gesullo F.; Mannelli F.; Fiaccabrino S.; Sordi B.; Paoli C.; Marone I.; Rumi E.; Manfredini R.; Barosi G.; Cazzola M.; Vannucchi A.M.; Guglielmelli P. (2019). Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation. BLOOD, vol. 133, pp. 2802-2808, ISSN:0006-4971 DOI Accesso ONLINE all'editore

Bartalucci, N; Mannelli, F; Contini, E; Romagnoli, S; Gianfaldoni, G; Scappini, B; Pelo, E; Pancani, F; Magi, A; Bosi, A; Guglielmelli, P; Vannucchi, AM (2019). THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS. In: HAEMATOLOGICA, FERRATA STORTI FOUNDATION, vol. 104, pp. 12-12.

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD (2019). Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). BLOOD, pp. 0-0, ISSN:0006-4971

Mimiola, Elda; Bomben, Riccardo; De Matteis, Giovanna; Perbellini, Omar; Guglielmelli, Paola; Bonifacio, Massimiliano; Parisi, Alice; Gattei, Valter; Zamò, Alberto; Mannelli, Francesco; García Montero, Andrés Celestino; Zanotti, Roberta (2019). Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. HEMATOLOGICAL ONCOLOGY, pp. 1-6, ISSN:0278-0232 DOI

Mannelli F.; Gesullo F.; Rotunno G.; Pacilli A.; Pieri L.; Guglielmelli P.; Vannucchi A.M. (2019). Validation of the Mayo alliance prognostic system for mastocytosis. BLOOD CANCER JOURNAL, vol. 9, pp. 18-21, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Innocenti, Rolando; Rigacci, Luigi; Restelli, Umberto; Scappini, Barbara; Gianfaldoni, Giacomo; Fanci, Rosa; Mannelli, Francesco; Scolari, Francesca; Croce, Davide; Bonizzoni, Erminio; Perrone, Tania; Bosi, Alberto (2019). Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. JOURNAL OF BLOOD MEDICINE, vol. 10, pp. 21-27, ISSN:1179-2736, DOVE MEDICAL PRESS LTD: DOI

Loscocco G.G.; Mannelli F.; Guglielmelli P.; Paoli C.; Marone I.; Cucci R.; Coltro G.; Sordi B.; Albano F.; Breccia M.; De Stefano V.; Finazzi G.; Iurlo A.; Martino B.; Palandri F.; Passamonti F.; Siragusa S.; Mannelli L.; Fantoni D.; Fazi P.; Amadori S.; Vignetti M.; Barbui T.; Vannucchi A.M. (2019). Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. E239-E242, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Magi, Alberto; Bolognini, Davide; Bartalucci, Niccoló; Mingrino, Alessandra; Semeraro, Roberto; Giovannini, Luna; Bonifacio, Stefania; Parrini, Daniela; Pelo, Elisabetta; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro Maria (2019). Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. BIOINFORMATICS, pp. 1-9, ISSN:1367-4803 DOI

Tefferi, Ayalew; Mudireddy, Mythri; Mannelli, Francesco; Begna, Kebede H; Patnaik, Mrinal M; Hanson, Curtis A; Ketterling, Rhett P; Gangat, Naseema; Yogarajah, Meera; De Stefano, Valerio; Passamonti, Francesco; Rosti, Vittorio; Finazzi, Maria Chiara; Rambaldi, Alessandro; Bosi, Alberto; Guglielmelli, Paola; Pardanani, Animesh; Vannucchi, Alessandro M (2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. LEUKEMIA, pp. 280-290, ISSN:1476-5551 DOI

Pacilli A.; Rotunno G.; Mannarelli C.; Fanelli T.; Pancrazzi A.; Contini E.; Mannelli F.; Gesullo F.; Bartalucci N.; Fattori G.C.; Paoli C.; Vannucchi A.M.; Guglielmelli P. (2018). Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. BLOOD CANCER JOURNAL, vol. 8, pp. 122-131, ISSN:2044-5385 DOI Accesso ONLINE all'editore

Pardanani A.; Shah S.; Mannelli F.; Elala Y.C.; Guglielmelli P.; Lasho T.L.; Patnaik M.M.; Gangat N.; Ketterling R.P.; Reichard K.K.; Hanson C.A.; Vannucchi A.M.; Tefferi A. (2018). Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models. BLOOD ADVANCES, vol. 2, pp. 2964-2972, ISSN:2473-9529 DOI Accesso ONLINE all'editore

Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M; Lasho, Terra L; Hanson, Curtis A; Ketterling, Rhett P; Begna, Kebede H; Naseema Gangat, null; Pardanani, Animesh; Vannucchi, Alessandro M (2018). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. LEUKEMIA, vol. 32, pp. 1631-1642, ISSN:1476-5551 DOI Accesso ONLINE all'editore

Mannelli, F; Ponziani, V; Bencini, S; Bonetti, Mi; Benelli, M; Cutini, I; Gianfaldoni, G; Scappini, B; Pancani, F; Piccini, M; Rondelli, T; Caporale, R; Gelli, Am; Peruzzi, B; Chiarini, M; Borlenghi, E; Spinelli, O; Giupponi, D; Zanghì, P; Bassan, R; Rambaldi, A; Rossi, G; Bosi, A (2017). CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.. HAEMATOLOGICA, pp. 529-540, ISSN:1592-8721 DOI

Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria (2017). A life-threatening ruxolitinib discontinuation syndrome. AMERICAN JOURNAL OF HEMATOLOGY, pp. 24775-24776, ISSN:0361-8609 DOI

Guglielmelli, Paola; Lasho, Terra L; Rotunno, Giada; Mudireddy, Mythri; Mannarelli, Carmela; Nicolosi, Maura; Pacilli, Annalisa; Pardanani, Animesh; Rumi, Elisa; Rosti, Vittorio; Hanson, Curtis A; Mannelli, Francesco; Ketterling, Rhett P; Gangat, Naseema; Rambaldi, Alessandro; Passamonti, Francesco; Barosi, Giovanni; Barbui, Tiziano; Cazzola, Mario; Vannucchi, Alessandro M; Tefferi, Ayalew (2017). MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, vol. 36, pp. 310-318, ISSN:0732-183X DOI Accesso ONLINE all'editore

Mannelli, Francesco; Ponziani, Vanessa; Bonetti, Maria Ida; Bencini, Sara; Cutini, Ilaria; Gianfaldoni, Giacomo; Scappini, Barbara; Pancani, Fabiana; Rondelli, Tommaso; Benelli, Matteo; Caporale, Roberto; Grazia Gelli, Anna Maria; Peruzzi, Benedetta; Longo, Giovanni; Bosi, Alberto (2015). Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. EXPERIMENTAL HEMATOLOGY, vol. 43, pp. 869-879, ISSN:0301-472X DOI Accesso ONLINE all'editore

Francesco Mannelli, Ilaria Cutini, Giacomo Gianfaldoni, Sara Bencini, Barbara Scappini, Fabiana Pancani, Vanessa Ponziani, Maria Ida Bonetti, Caterina Biagiotti, Giovanni Longo, Alberto Bosi (2014). CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia.. CYTOMETRY. PART B, CLINICAL CYTOMETRY, pp. 340-349, ISSN:1552-4949 DOI

Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A. (2013). A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.. CYTOMETRY. PART B, CLINICAL CYTOMETRY, vol. 84, pp. 71-81, ISSN:1552-4949 DOI

Peruzzi, Benedetta; Cutini, Ilaria; Gelli, Anna Maria Grazia; Rondelli, Tommaso; Statello, Marinella; Bencini, Sara; Mannelli, Francesco; Caporale, Roberto; Bosi, Alberto; Fanelli, Alessandra (2013). Diagnosis of a T-lineage acute Lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, vol. 6, pp. 77-80, ISSN:1179-142X DOI Accesso ONLINE all'editore

B. Scappini; G. Gianfaldoni; F. Caracciolo; F. Mannelli; C. Biagiotti; C. Romani; EM. Pogliani; F. Simonetti; L. Borin; R. Fanci; I. Cutini; G. Longo; MC. Susini; E. Angelucci; A. Bosi (2012). Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 1047-1051, ISSN:1096-8652 DOI

Scappini B;Gianfaldoni G;Caracciolo F;Mannelli F;Biagiotti C;Romani C;Pogliani EM;Simonetti F;Borin L;Fanci R;Cutini I;Longo G;Susini MC;Angelucci E;Bosi A (2012). Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 87, pp. 1047-1051, ISSN:0361-8609 DOI

Benevolo G;Stacchini A;Spina M;Ferreri AJ;Arras M;Bellio L;Botto B;Bulian P;Cantonetti M;Depaoli L;Di Renzo N;Di Rocco A;Evangelista A;Franceschetti S;Godio L;Mannelli F;Pavone V;Pioltelli P;Vitolo U;Pogliani EM;Fondazione Italiana Linfomi (2012). Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.. BLOOD, vol. 120, pp. 3222-3228, ISSN:0006-4971 DOI

Mannelli F;Bencini S;Peruzzi B;Cutini I;Sanna A;Benelli M;Magi A;Gianfaldoni G;Rotunno G;Carrai V;Gelli AM;Valle V;Santini V;Notaro R;Luzzatto L;Bosi A (2012). A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.. CYTOMETRY. PART B, CLINICAL CYTOMETRY, pp. 1-2, ISSN:1552-4949 DOI

Pagano L;Valentini CG;Pulsoni A;Fisogni S;Carluccio P;Mannelli F;Lunghi M;Pica G;Onida F;Cattaneo C;Piccaluga P;Di Bona E;Todisco E;Musto P;Spadea A;D'Arco A;Pileri S;Leone G;Amadori S;Facchetti F (2012). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.. HAEMATOLOGICA, pp. 1-2, ISSN:0390-6078 DOI

Bechini A; Boccalini S; Tiscione E; Pesavento G; Mannelli F; Peruzzi M; Rapi S; Mercurio S; Paolo Bonanni P (2012). Progress towards measles and rubella elimination in Tuscany,l Italy: the role of population seroepidemiological profile. EUROPEAN JOURNAL OF PUBLIC HEALTH, vol. 22, pp. 133-139, ISSN:1101-1262 DOI

Mannelli F;Gianfaldoni G;Intermesoli T;Cattaneo C;Borlenghi E;Cortelazzo S;Cavattoni I;Pogliani EM;Fumagalli M;Angelucci E;Romani C;Ciceri F;Corti C;Scattolin AM;Cortelezzi A;Mattei D;Audisio E;Spinelli O;Oldani E;Bosi A;Rambaldi A;Bassan R (2011). CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease.. HAEMATOLOGICA, vol. 97, pp. 568-571, ISSN:0390-6078 DOI

Gianfaldoni G;Mannelli F;Ponziani V;Longo G;Bencini S;Bosi A;Vannucchi AM (2010). Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.. HAEMATOLOGICA, vol. 95, pp. 833-836, ISSN:0390-6078 DOI

Gianfaldoni G; Mannelli F; Ponziani V; Longo G; Bencini S; Bosi A; Vannucchi AM. (2010). Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.. HAEMATOLOGICA, vol. 95(8), pp. 1435-1438, ISSN:0390-6078

Bassan R;Rossi G;Pogliani EM;Di Bona E;Angelucci E;Cavattoni I;Lambertenghi-Deliliers G;Mannelli F;Levis A;Ciceri F;Mattei D;Borlenghi E;Terruzzi E;Borghero C;Romani C;Spinelli O;Tosi M;Oldani E;Intermesoli T;Rambaldi A (2010). Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.. JOURNAL OF CLINICAL ONCOLOGY, vol. 28, pp. 3644-3652, ISSN:0732-183X DOI

C. Cellai; A. Laurenzana; E. Bianchi; S. Sdelci; R. Manfredini; A.M. Vannucchi; R. Caporale; M. Balliu; F. Mannelli; S. Ferrari; A. Bosi; D. Miniat; P.L. Cocco; S. Veronneau; J. Stankova; F. Paoletti (2009). Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. EXPERIMENTAL HEMATOLOGY, vol. 37, pp. 1176-1185, ISSN:0301-472X DOI Accesso ONLINE all'editore

E.Tiscione; A.Bechini; S.Boccalini; M.Peruzzi; F.Mannelli; P.Bonanni (2009). Sieroepidemiologia della rosolia in Toscana: strategie di vaccinazione per il recupero dei suscettibili.. In: XI Conferenza Nazionale di Sanità Pubblica “Prevenzione e Sanità Pubblica: modelli organizzativi e buone pratiche”., Napoli, 15-17 ottobre 2009, vol. Atti della XI Conferenza Nazionale di Sanità Pubblica “Prevenzione e Sanità Pubblica: modelli organizzativi e buone pratiche”., pp. 636-636.

B.Scappini; G. Gianfaldoni; P. Salvatore; MC. Susini; T. Izzo; F. Mannelli; G. Longo; R. Fanci; F. Ferrara; A. Bosi (2009). High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.. BLOOD, vol. 114, pp. 438-438, ISSN:0006-4971

Mannelli, F; De Simone, P; Gianfaldoni, G; Nozzoli, C; Filipponi, F; Bosi, Alberto (2009). Atypical acute leukemia early after liver transplantation.. TRANSPLANTATION PROCEEDINGS, vol. 41, pp. 3945-3946, ISSN:0041-1345

B. Scappini; G. Gianfaldoni; MC. Susini; R. Fanci; S. Baldini; R. Fjerza; F. Mannelli; G. Longo; A. Bosi (2009). High dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-Myl) in relapsed or refractory AML patients. HAEMATOLOGICA, vol. 94, pp. 549-549, ISSN:1592-8721

Gianfaldoni G;Mannelli F;Bencini S;Leoni F;Baldini S;Bosi A (2008). Peripheral blood blast clearance during induction therapy in acute myeloid leukemia.. BLOOD, vol. 111, pp. 1746-1747, ISSN:0006-4971 DOI

V. Ponziani; F. Mannelli; N. Bartalucci; G. Gianfaldoni; F. Leoni; E. Antonioli; P. Guglielmelli; S. Ciolli; A. Bosi; A. M. Vannucchi (2008). No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia.. LEUKEMIA, vol. 22, pp. 669-671, ISSN:0887-6924, Macmillan Magazines Limited:Porters South Crinian Street, London N1 9XW United Kingdom:011 44 207 8334000, 011 44 171 8434982, Fax: 011 44 207 812358: DOI

Gianfaldoni, G; Mannelli, F; Bencini, S; Leoni, F; Baldini, S; Bosi, Alberto (2008). Peripheral blood blast clearance during induction therapy in acute myeloid leukemia.. BLOOD, vol. 111, pp. 1746-1747, ISSN:0006-4971

Schubert, J; Hillmen, P; Röth, A; Young, Ns; Elebute, Mo; Szer, J; Gianfaldoni, G; Socié, G; Browne, P; Geller, R; Rother, Rp; Muus, P; Antonioli, E; Mannelli, F; Bosi, A; Rodeghiero, F (2008). Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.. BRITISH JOURNAL OF HAEMATOLOGY, pp. 263-272, ISSN:1365-2141

P. BONANNI; A. BECHINI; S. BOCCALINI; M. PERUZZI; E. TISCIONE; F. MANNELLI; G. BONCOMPAGNI; S. SALMASO; A. FILIA; M. CIOFI DEGLI ATTI (2007). Progress in Italy in control and elimination of measles and congenital rubella.. VACCINE, vol. 25, pp. 3105-3110, ISSN:0264-410X DOI Accesso ONLINE all'editore

Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi (2007). Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).. STEM CELLS, vol. 25, pp. 165-173, ISSN:1066-5099 DOI

GIANFALDONI G; MANNELLI F; M. BACCINI; ANTONIOLI E; LEONI F; BOSI A (2006). Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 134, pp. 54-57, ISSN:0007-1048

P. BONANNI; A. BECHINI; S. BOCCALINI; G. BONCOMPAGNI; F. MANNELLI; M. PERUZZI; F. ANSALDI; ML. CIOFI DEGLI ATTI (2006). Progress in Italy in control and elimination of measles and congenital rubella.. In: Vaccine Congress "Celebrating 25 years of Publication", Montreal (CANADA), 6-9 November 2006, vol. Acts of the Vaccine Congress "Celebrating 25 years of Publication", pp. 32-32.

V. Ponziani;G. Gianfaldoni;F. Mannelli;F. Leoni;S. Ciolli;P. Guglielmelli;E. Antonioli;G. Longo;A. Bosi;A. M. Vannucchi (2006). The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients.. LEUKEMIA, vol. 20, pp. 2074-2076, ISSN:0887-6924 DOI Accesso ONLINE all'editore

BECHINI A; PESAVENTO G; BOCCALINI S; TISCIONE E; BALOCCHINI E; GRAZIANI G; PECORI L; SANTINI MG; AZZARI C; PERUZZI M; MANNELLI F; TOMASI A; MONTOMOLI E; MAZZOLI F; P. BONANNI (2006). Implementazione del piano per l'eliminazione del morbillo e della rosolia congenita in Toscana: progressi verso la seconda fase di controllo dell'infezione.. NOTIZIARIO DELL'ISTITUTO SUPERIORE DI SANITÀ, vol. 19 (4), pp. 3-5, ISSN:0394-9303

E. ANTONIOLI; A. VANNUCCHI; A. BOSI; G. GIANFALDONI; F. MANNELLI (2005). Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report. JOURNAL OF CHEMOTHERAPY, vol. 17, pp. 449-451, ISSN:1120-009X

P. BONANNI; BECHINI A; PESAVENTO G; BOCCALINI S; TISCIONE E; GRAZIANI G; SANTINI M.G; BALOCCHINI E; PECORI L; PERUZZI M; MANNELLI F; TOMASI A; MONTOMOLI E (2005). Implementation of the Plan for Elimination of Measles and Congenital Rubella Infection in Tuscany: evidence of progress towards phase II of measles control. JOURNAL OF PREVENTIVE MEDICINE AND HYGIENE, vol. 46, pp. 111-117, ISSN:1121-2233

Gianfaldoni, G; Antonioli, E; Mannelli, F; Vannucchi, Am; Bosi, A. (2005). Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.. JOURNAL OF CHEMOTHERAPY, pp. 449-451, ISSN:1973-9478

Antonioli, E; Nozzoli, C; Gianfaldoni, G; Mannelli, F; Rossi, S; Betti, S; Bernardeschi, P; Fiorentini, G; Bosi, Alberto (2005). Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. ANNALS OF ONCOLOGY, vol. 16, pp. 1849-1850, ISSN:0923-7534, Attuale:OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP Kluwer Academic Publishers:Journals Department, PO Box 322, 3300 AH Dordrecht Netherlands:011 31 78 6576050, EMAIL: frontoffice@wkap.nl, kluweronline@wkap.nl, INTERNET: http://www.kluwerlaw.com, Fax: 011 31 78 6576254:

P. BONANNI; G. PESAVENTO; A. BECHINI; E. TISCIONE; F. MANNELLI; C. BENUCCI; A. LO NOSTRO (2003). Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.. VACCINE, vol. 21, pp. 685-691, ISSN:0264-410X DOI Accesso ONLINE all'editore

S. Ciolli ; F. Gigli; F. Mannelli ; R. Fanci ; A. Grossi ; G. Longo ; L. Rigacci ; A. Bosi (2003). High response rates and reduced first dose reactions with subcutaneous alemtuzumab in patients with relapsed and refractory CLL. BLOOD, vol. 102, pp. 357B-358B, ISSN:0006-4971

S. CIOLLI; F. GIGLI; R. FANCI; A. GROSSI; G. LONGO; L. RIGACCI; A. BOSI; F. MANNELLI (2003). SUBCUTANEOUS CAMPATH-1H IN REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: FEASIBILITY AND EFFICACY. In: XXXIX CONGRESSO SOCIETA' ITALIANA DI EMATOLOGIA, ROMA, SIE, pp. 10-11.

Francesco MANNELLI

Curriculum

Personal data

Date and place of birth: 17/12/1976, Prato (Italy)

Citizenship: Italian

Work address: Dip. Medicina Sperimentale e Clinica, University of Florence Largo Brambilla 3, 50134 Florence, Italy

Phone: +39 0557947824

E-mail: francesco.mannelli@unifi.it

Qualifications:

Degree in Medicine and Surgery obtained at the University of Florence

vote 110/110 cum laude dated 04/23/2002

Specialization in Hematology obtained at the University of Florence

vote 70/70 cum laude on 31/10/2006

Registration in the Register of the Order of Doctors n. 12908 of Florence since 14/12/2009 (previously registered in the Register of Doctors of Prato since 1/4/2003)

Work and/or professional experience:

From 01/11/2023 to today - University of Florence Largo Brambilla 3, 50134, Florence: Type B fixed-term researcher for the scientific disciplinary sector MED/15 at the Department of Experimental and Clinical Medicine.

From 12/12/2016 to 10/31/2022 - Careggi University Hospital (SSN), Largo Brambilla 3, 50134, Florence: Medical director at SOD Hematology, Center for Research and Innovation in Myeloproliferative Diseases (CRIMM).

From 01/28/2016 to 12/11/2016 - Careggi University Hospital (SSN), Largo Brambilla 3, 50134, Florence: Freelance professional contract as a full-time hematologist at the SOD Hematology for the development of the “Action undertaken to maintain the results achieved on the basis of previous projects financed by OTT” (project code 14MO07)

From 27/02/2014 to 26/02/2015 - Azienda Ospedaliero-Universitaria Careggi (SSN), Largo Brambilla 3, 50134, Florence: Freelance professional contract as a full-time hematologist doctor at the SOD Hematology for the development of the “Piano organizational CSE Tuscany Transplant Network through the establishment of a Regional CSE Transplant Coordination (CRTCSE)” (project code “13MOAB”

From 02/06/2012 to 12/05/2013 - Careggi University Hospital (SSN), Largo Brambilla 3, 50134, Florence: Inclusion in healthcare activities (employee service) at the SOD Hematology, on the existing researcher contract fixed-term, with a care profile with an hourly commitment of 33 hours per week (28 hours of assistance and 5 hours of teaching, 100% of the allowance pursuant to Legislative Decree 517/99)

From 01/11/2008 to 05/12/2013 – University of Florence (Other Public Administration), Largo Brambilla 3, 50134, Florence: Fixed-term researcher contract (individual fixed-term subordinate employment contract) full for the research project "Clearance of peripheral blasts during induction therapy in adult patients suffering from Acute Myelogenous Leukemia". Teaching of Hematology at the Schools of Medicine, Nursing and Biotechnology of the University of Florence.

From January 2007 to January 2012 - Dr Settimelli srl Analysis Laboratory, Via della Querciola 12, Sesto Fiorentino (FI): freelance contract as a haematologist for cyto-morphological consultancy.

From 01/09/2004 to 28/02/2008 – Florentine Institute of Care and Assistance, private nursing homes affiliated with the NHS Villa Glicini (Via del Pergolino 4/6, Florence) and Villa Santa Chiara (P.zza Indipendenza, Florence); freelance doctor contract for carrying out medical on-call activities at night and on holidays.

Other activities carried out:

April 2024: Principal Investigator of the project “APL-like subset within NPM1-mutated acute myeloid leukemia: a distinct phenotypic signature correlating with early-onset vascular complications” worthy of funding within the 2024 Call for Ideas promoted by the GIMEMA group.

November 2023: Scientific secretariat and chairman at the third annual congress of the RIMA Association (Italian Mastocytosis Network), Florence headquarters, Grand Hotel Baglioni

September 2021: Scientific secretary, chairman and speaker at the international preceptorship “Systemic mastocytosis: a multidisciplinary approach”, Department of Experimental and Clinical Medicine, University of Florence.

From 01/01/2014 to 11/12/2016 - University of Florence (Other Public Administration), Largo Brambilla 3, 50134, Florence: Research grant of a healthcare nature at the SOD Hematology (Head Prof. A Bosi). Title of the research project: “Study of multi-lineage dysplasia via flow cytometry in acute myeloid leukemia”

From 02/03/2008 to 31/05/2008 - Internship lasting 3 months at the General Cytometry Service of the University of Salamanca, Spain, directed by Prof. Alberto Orfao, thein which knowledge was perfected in various flow cytometry techniques on acute leukemias, myelodysplastic syndromes, multiple myeloma and chronic lymphoproliferative syndromes; during the aforementioned period, attendance of the seminars of the PhD course in Flow Cytometry.

From 01/11/2006 to 30/10/2008 - University of Florence (Other Public Administration), Largo Brambilla 3, 50134, Florence: Research grant of a welfare nature at the SOD Hematology (Head Prof. A Bosi). Title of the research project "Flow cytometric study of the normal and leukemic stem compartments in patients suffering from Acute Myeloid Leukemia and possible applications in the evaluation of minimal residual disease".

In various professional experiences, from 2006 to today, clinical activity at the Onco-Hematological Inpatient Unit, Bone Marrow Transplant, and the Center for Research and Innovation in Myeloproliferative Diseases (CRIMM) with the acquisition of consolidated experience in the diagnostics and clinical management of patients suffering from neoplasms haematological, also in the context of experimental clinical protocols of various phases (from 1 to 3). From 2008 to 2016, head of the Cytometry Laboratory, from which consolidated experience in diagnostics (including the evaluation of cyto-morphological preparations) and in the monitoring of minimal residual disease of hematological neoplasms (and in particular acute leukemias, lymphoproliferative syndromes, myelodysplastic syndromes) , experience proven by external quality controls UK Neqas and EuroFlow.

Research activity:

2021: achievement of national scientific qualification as 2nd level professor. Notice of D.D. 2175/2018 Competition sector 06/D3 Blood diseases, Oncology and Rheumatology.

2021: Thesis co-supervisor of the School of Specialization in Hematology entitled “Hereditary Alpha Tryptasemia in Mastocytosis: analysis of a series of 444 patients”

Thesis supervisor for master’s degree (LM-41) in Medicine and Surgery entitled "Venetoclax-based regimens for relapsed/refractory acute myeloid leukemia. Experience on 47 patients".

2021: Member of the writing committee and co-Principal Investigator for the conception, drafting and management of the prospective multicenter clinical protocol ENABLE in acute myeloid leukemia secondary to myeloproliferative neoplasia (EudraCT number 2020-006114-20) within the Italian Group Adult Hematological Diseases (GIMEMA AML 2420).

2021: Member of the Francesca Martini Award commission for an Experimental Thesis in Oncohematology 2021 promoted by the NANA ONLUS association.

2020: Qualification of Hematology subject expert, MED/15 sector, at the University of Florence.

2016-2020: Principal Investigator for the conduct of the research project “Peripheral blast clearance analysis during induction treatment in patients with acute myeloid leukemia” (project code GR-2013-02358238) financed by the Ministry of Health (Finalized Research Call 2013 – Young Researchers Section). The project had previously obtained funding from the Istituto Toscano Tumori, the Tuscany Region and Ente Cassa di Risparmio Firenze and was included in the context of the multicenter AML 02-06 treatment protocol of the Northern Italy Leukemia Group (NILG).

2019: Member of the working group for the AML Academy project promoted by the National Academy of Medicine for the dissemination of new scientific evidence and their application in clinical practice in the field of acute myeloid leukemia (https://amla.accmed.org/ board)

2019: Member of the writing committee and co-Principal Investigator for the conception, drafting and management of the prospective multicenter clinical protocol AMELIORATE in acute myeloid leukemia (EudraCT code 2019-003936-21) within the Italian Group of Hematological Diseases of Adult (GIMEMA AML 1919)

2018: Member of the core team of the Research Unit of the University of Florence within the MYeloid NEoplasms VentuRe AIRC (MYNERVA) group for the conduct of the research program “Actionable targets in clonal progression and systemic spreading of myeloid neoplasms” supported by the Italian Association Cancer Research (AIRC) - 5 per Mille research program 2018 (ID code 21267

2014-2018: Scientific manager for the SOD Hematology Unit of the AOU Careggi for the conduct of the research project: “Detecting copy number variants from whole-exome sequencing data applied to acute myeloid leukemia” (project CUP code D12I14000580001) financed by the Ministry of Health (Finalized Research Call 2012 – Young Researchers Section).

2013: Co-supervisor for master’s degree thesis (LM-41) in Medicine and Surgery entitled "Systematic study of minimal residual disease in acute myeloid leukemia: from technique to clinical application"

2012-2016: Conception, planning and management of the “Monitoring of chimerism on sorted peripheral CD34+ cells in patients with acute leukemia receiving allogeneic bone marrow transplant”, funded by the Ministry of Health and the Tuscany Region (Finalized Research Call 2009; project CUP code D11J09000190003)

2007-2014: Member of the Scientific Committee of the Northern Italy Leukemia Group (NILG), in particular for the drafting and management of the NILG 02-06 clinical protocol in the field of acute myeloid leukemia (www.clinicaltrials.gov ID #NCT00495287)

2015-2017: Member of the expert panel of the Italian Cytometry Group (GIC) for the project “Acute Leukemias immunophenotyping by flow cytometry: methods and clinical value”.

Reviewer of articles for the scientific journals Blood, Haematologica, Experimental Hematology, Leukemia Research, Journal of Clinical Laboratory Analysis, Journal of Hematology and Oncology. Member of the editorial board of the Journal of Blood Disorders and Medicine (ISSN-2470-9956).

Conference papers as first author:

Speaker of the study proposal "Acute leukemias arising in MPN" at the European Leukemia Net Symposium on 04/18/2023 in Mannheim, Germany

Oral communication selected as first author entitled “Third generation sequencing of normal karyotype acute myeloid leukemia: identification of a disease subset with unfavorable prognosis. A MYNERVA-GIMEMA collaborative study. Authors: Mannelli F, Bartalucci N, Romagnoli S, Gianfaldoni G, Piccini M, Scappini B, Pelo E, Pancani F, Vanderwert F, Maccari C, Signori L, Piciocchi A, Crea E, Fazi P, Vignetti M, Venditti A, Buccisano F, Voso MT, Amadori S, Guglielmelli P, Vannucchi AM. Congress: XVII National Congress of the Italian Society of Experimental Hematology 2022. Venue: Rome, Italy. Date: 31/3-2/4/2022

Oral communication selected as first author entitled “Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in myelofibrosis”. Authors: Mannelli F, Bencini S, Coltro G, Loscocco G, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Vannucchi AM, Guglielmelli P. Congress: XVII National Congress of the Italian Society of Experimental Hematology 2022. Venue: Rome, Italy. Date: 31/3-2/4/2022

Speaker in the educational session "Hypereosinophilic syndromes and mastocytosis" with a report entitled "The treatment of systemic mastocytosis and eosinophilic disorders: from supportive to targeted" at the 47th National Congress of the Italian Hematology Society 2019. Location: Rome. Date: 7-9/10/2019

Oral communication as first author entitled “Early peripheral blast cell clearance predicts minimal residual disease status after induction in acute myeloid leukemia”. Authors: Mannelli F, Gianfaldoni G, Cutini I, Bencini S, Bonetti MI, Piccini M, Scappini B, Ponziani V, Pancani F, Bosi A Scientific journal: HAEMATOLOGICA Volume: 100 Supplement: 3 Pages: 42. Congress: 45th Congress of the Italian Society of Hematology. Headquarters: Florence, ITALY; Date: 4-7/10/2015

Oral communication as first author entitled “Multi-lineage dysplasia as assessed by immuno-phenotype has no impact on clinical-biological characteristics and outcome of acute myeloid leukemia with mutated nucleophosmin (NPM1)”. Authors: Mannelli F, Bencini S, Gianfaldoni G, Ponziani V, Cutini I, Scappini B, Pancani F, Biagiotti C, Bonetti MI, Longo G, Bosi A. Congress proceedings. Congress: 31st Congress of the Italian Cytometry Society. Headquarters: Lucca, ITALY; Date: 8-11/10/2013

Speaker in the educational session "Minimal Residual Disease" with a report entitled "MRD in flow cytometry" at the National Congress of the Italian Bone Marrow Transplant Group (GITMO). Headquarters: Florence, Italy. Date: 5-6/5/2011

Oral communication as first author entitled “The phenotypic profile of whole bone marrow cells provides clustering of genetic subtypes in acute myeloid leukemia”. Authors: Mannelli F, Bencini S, Cutini I, Gianfaldoni G, Benelli M, Magi A, Pancani F, Ponziani V, Biagiotti C, Scappini B, Bosi A. Scientific journal: CYTOMETRY PART B-CLINICAL CYTOMETRY Volume: 80B Issue: 6 Pages: 397-397. Congress: 11th Annual Meeting of the European Society for Clinical Cell Analysis (ESCCA). Headquarters: Dublin, IRELAND; Date: 14-17/09/2011

Awards:

GIC Award – Italian Society of Cytometry – 2013: special mention for the article “CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia

Book chapters:

Author of the chapter on Acute Leukemia for the volume “Manual of Blood Diseases” ed. Elsevier year 2012.

Author of the chapter “Immunophenotyping of acute leukemias – from biology to clinical application” ed. Intech year 2016

Publications:

Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report. Ciolli G, Pasquini A, Mannelli F, Scappini B, Gianfaldoni G, Quinti E, Fasano L, Caroprese J, Crupi F, Vannucchi AM, Piccini M. Ther Adv Hematol. 2024 Sep 23;15:20406207241270846. doi: 10.1177/20406207241270846. eCollection 2024. PMID: 39328469

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting. Ciolli G, Piccini M, Mannelli F, Gianfaldoni G, Scappini B, Fasano L, Crupi F, Quinti E, Pasquini A, Caroprese J, Rotunno G, Pancani F, Signori L, Maccari C, Vanderwert FI, Guglielmelli P, Vannucchi AM.

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L, Pessina C, Colugnat I, Aquila R, Balliu M, Maccari C, Romagnoli S, Paoli C, Nacca E, Fagiolo L, Maffioli M, Barbui T, Passamonti F, Vannucchi AM. Am J Hematol. 2024 Aug;99(8):1550-1559. doi: 10.1002/ajh.27400. Epub 2024 Jun 6. PMID: 38841874

Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal. Tanasi I, Crosera L, Taus F, Orsolini G, Adami G, Olivieri F, Bernardelli A, Bonadonna P, Nalin F, Sella S, Giannini S, Liu Y, Mannelli F, Vanderwert F, Bonifacio M, Krampera M, Rossini M, Lyons JJ, Zanotti R.

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib. Coltro G, Capecchi G, Maffioli M, Mannelli F, Mora B, Atanasio A, Iurlo A, Maccari C, Farina M, Nacca E, Caramella M, Signori L, Borella M, Bertù L, Esposito M, Guglielmelli P, Passamonti F, Vannucchi AM.

Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis. Sciumè M, Serpenti F, Zanotti R, Bonadonna P, Tanasi I, Crosera L, Elena C, Mannelli F, Crupi F, Papayannidis C, Sartor C, Soverini S, Rondoni M, Eller-Vainicher C, Pravettoni V, Rivolta F, Alberti Violetti S, Croci GA, Migliorini AC, Bolli N, Giannarelli D, Grifoni FI. Hematol Oncol. 2024 May;42(3):e3277. doi: 10.1002/hon.3277. PMID: 38682493

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, Vannucchi AM, Guglielmelli P. Blood Cancer J. 2024 Jan 18;14(1):10. doi: 10.1038/s41408-023-00968-7. PMID: 38238287 Free PMC article.

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis. Mannelli F, Crupi F, Zanotti R, Pagano L, Rapezzi D, Tanasi I, Criscuolo M, Bonifacio M, Fresa A, Guglielmelli P, Vannucchi AM. Ther Adv Hematol. 2023 Nov 2;14:20406207231205643. doi: 10.1177/20406207231205643. eCollection 2023. PMID: 37929078

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Am J Hematol. 2023 Oct 17. doi: 10.1002/ajh.27136. Online ahead of print. PMID: 37846894

A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, Hanson CA, Ketterling RP, De Stefano V, Carobbio A, Barbui T, Guglielmelli P, Gangat N, Vannucchi AM. Am J Hematol. 2023 Sep 4. doi: 10.1002/ajh.27079. Online ahead of print. PMID: 37665758

Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.Loscocco GG, Ascani S, Mannelli F, Zanelli M, Rotunno G, Santi R, Vannucchi AM. Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026. Online ahead of print. PMID: 37435901

Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. Calabresi L, Carretta C, Romagnoli S, Rotunno G, Parenti S, Bertesi M, Bartalucci N, Rontauroli S, Chiereghin C, Castellano S, Gentili G, Maccari C, Vanderwert F, Mannelli F, Della Porta M, Manfredini R, Vannucchi AM, Guglielmelli P. Am J Hematol. 2023 Oct;98(10):1520-1531. doi: 10.1002/ajh.27013. Epub 2023 Jul 3. PMID: 37399248

Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia. Mannelli F, Piccini M, Bencini S, Gianfaldoni G, Peruzzi B, Caporale R, Scappini B, Fasano L, Quinti E, Ciolli G, Pasquini A, Crupi F, Pilerci S, Pancani F, Signori L, Tarantino D, Maccari C, Paradiso V, Annunziato F, Guglielmelli P, Vannucchi AM.

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Piccini M, Mannelli F, Coltro G. Bioengineering (Basel). 2023 May 13;10(5):591. doi: 10.3390/bioengineering10050591. PMID: 37237661 Review.

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project. Coltro G, Sant'Antonio E, Palumbo GA, Mannelli F, De Stefano V, Ruggeri M, Elli EM, Zanotti R, Borsani O, Bertozzi I, Duminuco A, Betti S, Carli G, Cavalca F, Tanasi I, Rumi E, Randi ML, Garibaldi B, Loscocco GG, Guglielmelli P, Vannucchi AM. Cancer Med. 2023 Jan 27. doi: 10.1002/cam4.5618. PMID: 36708083

ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. Mannelli F, Guglielmelli P, Fazi P, Crea E, Piciocchi A, Vignetti M, Amadori S, Pane F, Venditti A, Vannucchi AM. Future Oncol. 2023 Jan 18. doi: 10.2217/fon-2022-0512. PMID: 36651780

Diagnostic and therapeutic challenges in mast cell sarcoma. Mannelli F, Gesullo F, Mannarelli C, Vanderwert F, Lazzi S, Mungai F, Berti V, Santi R, Guglielmelli P, Vannucchi AM. Am J Hematol. 2023 Mar;98(3):529-532. doi: 10.1002/ajh.26804. PMID: 36464921

Disease correlates and clinical relevance of Hereditary Alpha-Tryptasemia in patients with Systemic Mastocytosis. Sordi B, Vanderwert F, Crupi F, Gesullo F, Zanotti R, Bonadonna P, Crosera L, Elena C, Fiorelli N, Ferrari J, Grifoni F, Sciumè M, Parente R, Triggiani M, Palterer B, Mecheri V, Almerigogna F, Santi R, Di Medio L, Brandi ML Iorno ML, Ciardetti I, Bencini S, Annunziato F, Mannarelli C, Pieri L, Guglielmelli P, Mannelli F*, Vannucchi AM* (*co-last authors). Journal of Clin Immunol and Allergy 2023 Feb;151(2):485-493.e11. doi: 10.1016/j.jaci.2022.09.038

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Coltro G, Mannelli F, Loscocco GG, Mannarelli C, Rotunno G, Maccari C, Pancani F, Atanasio A, Vannucchi AM, Guglielmelli P. Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6. PMID: 35961958

Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management. Crupi F, Sordi B, Vanderwert F, Gesullo F, Amorosi A, Mannelli F, Santi R. Int J Mol Sci. 2022 Aug 7;23(15):8772. doi: 10.3390/ijms23158772. PMID: 35955907

SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. Loscocco GG, Guglielmelli P, Mannelli F, Mora B, Mannarelli C, Rotunno G, Pancani F, Maccari C, Bartalucci N, Romagnoli S, Coltro G, Passamonti F, Vannucchi AM. Am J Hematol. 2022 Sep;97(9):E347-E349; doi: 10.1002/ajh.26648. Epub 2022 Jul 15. PMID: 35796725

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. Loscocco GG, Santi R, Carrai V, Coltro G, Mannelli F, Guglielmelli P, Vannucchi AM. Int J Lab Hematol. 2022 May 27. doi: 10.1111/ijlh.13902. Epub ahead of print. PMID: 35622069.

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Guglielmelli P, Vannucchi AM. Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31. PMID: 35338671

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Guglielmelli P, Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, Maccari C, Paoli C, Romagnoli S, Bartalucci N, Vannucchi AM. Blood Adv. 2022 May 10;6(9):2927-2931. doi: 10.1182/bloodadvances.2021006350. PMID: 35020812

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, Coltro G, Betti S, Maccari C, Ceglie S, Chiusolo P, Paoli C, Barbui T, Tefferi A, De Stefano V, and Vannucchi AM. Blood Cancer Journal 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. Romagnoli S, Bartalucci N, Gesullo F, Balliu M, Bonifacio S, Fernandez AGL, Mannelli F, Bolognini D, Pelo E, Mecucci C, Guglielmelli P and Vannucchi AM. Biomarker Research 2021; 9(83):1-4; doi: 10.1186/s40364-021-00337-1

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of ERNEST Study. Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larran A, Andreasson BI, Vannucchi AMM, Barbui T. Blood Adv. 2021 Nov 9:bloodadvances.2021006006. doi: 10.1182/bloodadvances.2021006006.

AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. Mannelli F, Gianfaldoni G, Guglielmelli P, Buccisano F, Caporale R, Chiarini M, Rossi G, Venditti A, Fazi P, Crea E, Piciocchi A, Voso MT, Vignetti M, Amadori S, Vannucchi AM. Future Oncol. 2021 Oct;17(29):3787-3796. doi: 10.2217/fon-2021-0388. Epub 2021 Jul 13. PMID: 34254530

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK.

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Am J Hematol. 2021 Apr 12. doi: 10.1002/ajh.26186. PMID: 33844862

Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. Loscocco GG, Antonioli E, Romano I, Vergoni F, Rotunno G, Mannelli F, Guglielmelli P, Vannucchi AM. Am J Hematol. 2021 Jun 1;96(6):749-754. doi: 10.1002/ajh.26153. Epub 2021 Mar 29. PMID: 33719069

Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series.Tanasi I, Bonifacio M, Pizzolato M, Irene Grifoni F, Sciumè M, Elena C, Benvenuti P, Mannelli F, Parente R, Schena D, Scaffidi L, Bonadonna P, Papayannidis C, Rondoni M, Criscuolo M, Vannucchi AM, Triggiani M, Martinelli G, Krampera M, Zanotti R. Br J Haematol. 2021 May;193(4):845-848. doi: 10.1111/bjh.17405. Epub 2021 Mar 22. PMID: 33754335

Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease. Mannelli F. J Clin Med. 2021 Jan 23;10(3):436. doi: 10.3390/jcm10030436. PMID: 33498691 Free PMC article. Review.

BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Loscocco GG, Rotunno G, Mannelli L, Mannelli F, Vergoni F, Guglielmelli P, Vannucchi AM.

Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature. Berti PP, Pirillo V, Rizzo P, Ria A, Mannelli F, Broger M. Br J Neurosurg. 2020 Nov 28:1-3. doi: 10.1080/02688697.2020.1849549. PMID: 33249871

Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis. Mannelli F. Ann Hematol. 2020 Nov 6:1-8. doi: 10.1007/s00277-020-04323-9. PMID: 33156374

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. Mannelli F, Bencini S, Piccini M, Gianfaldoni G, Bonetti MI, Peruzzi B, Caporale R, Scappini B, Pancani F, Ponziani V, Signori L, Zizza M, Annunziato F, Bosi A. Cancers (Basel). 2020 Oct 30;12(11):E3196. doi: 10.3390/cancers12113196. PMID: 33143086

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Caprioli C, Lussana F, Salmoiraghi S, Cavagna R, Buklijas K, Elidi L, Zanghi' P, Michelato A, Delaini F, Oldani E, Intermesoli T, Grassi A, Gianfaldoni G, Mannelli F, Ferrero D, Audisio E, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Cavattoni I, Tajana M, Scattolin AM, Mattei D, Corradini P, Campiotti L, Ciceri F, Bernardi M, Todisco E, Cortelezzi A, Falini B, Pavoni C, Bassan R, Spinelli O, Rambaldi A.

Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML. Mannelli F*, Gianfaldoni G*, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A. (*co-first authors) Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25942.

A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. Loscocco GG, Mannelli F, Mannelli L, Vergoni F, Gesullo F, Rotunno G, Guglielmelli P, Vannucchi AM. Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T. Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2.

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature Coltro G, Mannelli F, Vergoni F, Santi R, Massi D, Siliani LM, Marzullo A, Bonifacio S, Pelo E, Pacilli A, Paoli C, Franci A, Calabresi L, Bosi A, Vannucchi AM, Guglielmelli P. Clin Exp Med. 2020 May;20(2):313-320. doi: 10.1007/s10238-020-00616-5.

Health technology assessment-based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. Gaipa G, Erba E, Danova M, Mazzini G, Venditti A, Buldini B, Specchia G, Maglia O, Kunkl A, Ciriello MM, Arpinati M, Mannelli F, Lanza F, Riccioni R, Pistotti V, Apolone G; Società Italiana di Citometria (GIC).

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462.

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Gianfaldoni G*, Mannelli F*, Intermesoli T, Bencini S, Giupponi D, Farina G, Cutini I, Bonetti MI, Masciulli A, Audisio E, Ferrero D, Pavoni C, Scattolin AM, Bosi A, Rambaldi A, Bassan R. (*co-first authors) Blood Adv. 2020 Jan 28;4(2):301-311. doi: 10.1182/bloodadvances.2019000406.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Lurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM. Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677.

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. Guglielmelli P, Pacilli A, Coltro G, Mannelli F, Mannelli L, Contini E, Rotunno G, Bartalucci N, Fiaccabrino S, Sordi B, Loscocco GG, Paoli C, Vannucchi AM. Am J Hematol. 2019 Oct 29. doi: 10.1002/ajh.25668.

Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, Bonifacio M, Parisi A, Gattei V, Zamò A, Mannelli F, García Montero AC, Zanotti R. Hematol Oncol. 2019 Sep 16. doi: 10.1002/hon.2680. [Epub ahead of print]

Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM. Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25555

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P.

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. Mannelli F, Gesullo F, Rotunno G, Pacilli A, Bencini S, Annunziato F, Zanotti R, Scaffidi L, Giona F, Santopietro M, Grifoni F, Pieri L, Guglielmelli P, Vannucchi AM. Am J Hematol. 2019 May 6. doi: 10.1002/ajh.25506

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Magi A, Bolognini D, Bartalucci N, Mingrino A, Semeraro R, Giovannini L, Bonifacio S, Parrini D, Pelo E, Mannelli F, Guglielmelli P, Vannucchi AM.

A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. Grifoni FI, Sciumè M, Pravettoni V, Ulivieri FM, Muratori S, Fracchiolla NS, Tagliaferri E, Gianelli U, Migliorini AC, Cro L, Pacilli A, Mannelli F, Baldini L. Hematol Oncol. 2019 Apr;37(2):205-211 doi: 10.1002/hon.2605

Validation of the Mayo alliance prognostic system for mastocytosis. Mannelli F, Gesullo F, Rotunno G, Pacilli A, Pieri L, Guglielmelli P, Vannucchi AM. Blood Cancer J. 2019 Feb 11;9(2):18.

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A. J Blood Med. 2018 Dec 27;10:21-27.

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P. Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A. Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886

A life-threatening ruxolitinib discontinuation syndrome. Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM. Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775

CEBPA–double mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AMG, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A Haematologica 2017; 102(3):529-540. doi: 10.3324/haematol.2016.151910

Immunophenotyping of acute leukemias: insight into prognosis since the outset Mannelli F J Blood Dis Med 2016

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, Oldani E, Tosi M, Grassi A, Parolini M, Audisio E, Cattaneo C, Raimondi R, Angelucci E, Cavattoni IM, Scattolin AM, Cortelezzi A, Mannelli F, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Romani C, Bassan R, Rambaldi A. Biol Blood Marrow Transplant. 2016 Aug 1. pii: S1083-8791(16)30257-9. doi: 10.1016/j.bbmt.2016.07.021

Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biologic features and outcome of NPM1-mutated acute myeloid leukemia. Mannelli F, Ponziani V, Bonetti MI, Bencini S, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Rondelli T, Benelli M, Caporale R, Gelli AMG, Peruzzi B, Longo G, Bosi A. Exp Hematol. 2015;43(10):869. doi: 10.1016/j.exphem.2015.06.003

CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Mannelli F, Cutini I, Gianfaldoni G, Bencini S, Scappini B, Pancani F, Ponziani V, Bonetti MI, Biagiotti C, Longo G, Bosi A. Rivista Scientifica: Cytometry B Clin Cytom 2014;86:340. doi: 10.1002/cyto.b.21156

Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. Peruzzi B, Cutini I, Gelli AM, Rondelli T, Statello M, Bencini S, Mannelli F, Caporale R, Bosi A, Fanelli A. Int Med Case Rep J. 2013;6:77. doi: 10.2147/IMCRJ.S49278

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: a retrospective Italian multicentric study Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Gaidano G, Pica G, Onida F, Cattaneo C, Piccaluga PP, Rodeghiero F, Todisco E, Leone G, Pileri S, Amadori S, Facchetti F for GIMEMA-ALWP* (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Haematologica 2012; 98(2): 239. doi: 10.3324/haematol.2012.072645

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Benevolo G, Stacchini A, Spina M, Arras M, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Ferreri A, Franceschetti S, Godio L, Mannelli F, Pavone L, Pioltelli P, Vitolo U, Pogliani EM. Blood 2012; 120(16): 3222. doi: 10.1182/blood-2012-04-423095

A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI-deficiency in Paroxysmal Nocturnal Hemoglobinuria. Mannelli F, Bencini S, Peruzzi B, Cutini I, Sanna A, Benelli M, Magi A, Gianfaldoni G, Rotunno G, Carrai V, Gelli AMG, Valle V, Santini V, Notaro R, Luzzatto L, Bosi A. Cytometry Part B 2013;84(2):71. doi: 10.1002/cyto.b.21064

Cytarabine and Clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Angelucci E, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Bosi A. Am J Hematol 2012; 87(12): 1047. doi: 10.1002/ajh.23308

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, Romani C, Ciceri F, Corti C, Scattolin A, Cortelezzi A, Mattei D, Audisio E, Spinelli O, Oldani E, Bosi A, Rambaldi A, Bassan R. Haematologica 2012; 97 (4): 568. doi: 10.3324/haematol.2011.054064

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Journal of Clinical Oncology 2010; 28 (22): 3644. doi: 10.1200/JCO.2010.28.1287

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease-free and overall survival in acute myeloid leukemia. Gianfaldoni G*, Mannelli F*, Ponziani V, Longo G, Bencini S, Bosi A and Vannucchi AM. (*co-first authors) Haematologica 2010; 95 (5): 833. doi: 10.3324/haematol.2009.011908

Atypical Acute Leukemia Early After Liver Transplantation. Mannelli F, De Simone P, Gianfaldoni G, Nozzoli C, Filipponi F and Bosi A. Transplantation Proceedings 2009 (41): 3945. doi: 10.1016/j.transproceed.2009.06.194

Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J and Paoletti F. Experimental Hematology 2009; 37 (10): 1176. doi: 10.1016/j.exphem.2009.07.002

Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. Gianfaldoni G*, Mannelli F*, Bencini S, Leoni F, Baldini S, Bosi A (*co-first authors) Blood 2008; 111: 1746. doi: 10.1182/blood-2007-10-121103

No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. Ponziani V, Mannelli F, Bartalucci N, Gianfaldoni G, Leoni F, Antonioli E, Guglielmelli P, Ciolli S, Bosi A, Vannucchi AM. Leukemia 2008; 22 (3): 669. doi: 10.1038/sj.leu.2404938

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’ Tumor gene 1 (WT1). Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Busse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. Stem Cells 2007; 25(1): 165. doi: 10.1634/stemcells.2006-0351

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Ponziani V, Gianfaldoni G, Mannelli F, Leoni F, Ciolli S, Guglielmelli P, Antonioli E, Longo G, Bosi A and Vannucchi AM. Leukemia 2006; 1(4): 302. doi: 10.1038/sj.leu.2404368

Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Gianfaldoni G, Mannelli F, Antonioli E, Vannucchi AM and Bosi A. Br J Haematol. 2006 Jul;134(1): 54. doi: 10.1111/j.1365-2141.2006.06100.x

Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Antonioli E, Nozzoli C, Gianfaldoni G, Mannelli F, Rossi S, Betti S, Bernardeschi P, Fiorentini G and Bosi A. Ann Oncol 2005; 16(11): 1849. doi: 10.1093/annonc/mdi357

Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with Rituximab: case report. Gianfaldoni G, Antonioli E, Mannelli F, Vannucchi AM and Bosi A. Journal of Chemotherapy 2005; 17 (4): 449. doi: 10.1179/joc.2005.17.4.449